<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1819_S06_C25_p325-360</title>
		<link href="BCSC1819_S06_C25_p325-360-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1819_S06_C25_p325-360" lang="en-US">
		<div id="_idContainer009" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter</span><span class="cn-chap"> </span>25</p>
			<p class="chapter-title">Disorders of the Retina and Vitreous</p>
			<p class="video-list-mid ParaOverride-1"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;<span class="italic">This chapter includes related videos, which can be accessed by scanning the QR codes provided in the text or &#173;going to </span><a href="http://www.aao.org/bcscvideo_section06"><span class="italic">www.&#173;aao.&#173;org/&#173;bcscvideo_&#173;section06</span></a><span class="italic">.</span></p>
			<p class="body-text--no-indent- ParaOverride-2">This chapter focuses on ret&#173;i&#173;nal diseases that are most often diagnosed in the first 2 de&#173;cades of life. &#173;These include retinopathy of prematurity, Leber congenital amaurosis, and retinoblastoma. Many of the topics covered in this chapter are also discussed in BCSC Section&#160;12, <span class="italic">Ret&#173;ina and Vitreous.</span> See BCSC Section&#160;4, <span class="italic">Ophthalmic Pathology and Intraocular Tumors,</span> for detailed discussion of tumors.</p>
			<p class="h1 ParaOverride-3">Congenital and Developmental Abnormalities</p>
			<div id="Chapt25_Top1">
			<p class="h2-h1 ParaOverride-4">Persistent Fetal Vasculature</p>
			<p class="body-text--no-indent-">Per&#173;sis&#173;tent fetal vasculature is covered in <span class="xref-local">Chapter&#160;23</span>.</p>
			<p class="h2 ParaOverride-5">Retinopathy of Prematurity</p>
			<p class="body-text--no-indent-">Retinopathy of prematurity (ROP) is a vasoproliferative ret&#173;i&#173;nal disorder unique to premature infants. First described in the 1950s, ROP is a leading cause of childhood blindness in the United States, second only to ce&#173;re&#173;bral visual impairment.</p>
			<p class="h3 ParaOverride-5">Pathophysiology</p>
			<p class="body-text--no-indent-">Ret&#173;i&#173;nal vascularization begins during week 16 of gestation. Mesenchymal tissue (the source of ret&#173;i&#173;nal vessels) grows centrifugally from the optic disc, reaching the nasal ora serrata by 36 weeks’ gestation and the temporal ora serrata by 40 weeks’ gestation. ROP results from abnormal growth of &#173;these ret&#173;i&#173;nal blood vessels in premature infants &#173;because of a complex interaction between vascular endothelial growth &#173;factor (VEGF) and insulin-&#173;like growth &#173;factor I (IGF-&#173;I). The pathophysiology of ROP is currently thought of as a 2-&#173;phase pro&#173;cess and is outlined in <span class="xref-table">&#173;Table&#160;25-1</span>.</p>
			<p class="h3 ParaOverride-5">Classification</p>
			<p class="body-text--no-indent-">The International Classification of Retinopathy of Prematurity (ICROP) describes the disease by location (zone), stage, and extent (<span class="xref-table">&#173;Table&#160;25-2</span>; <span class="xref-figure">Figs 25-1 through 25-5</span>). Higher stage numbers and lower zone numbers indicate more severe ROP.</p>
			<p class="body-text"><span class="italic">Plus disease</span> refers to marked arteriolar tortuosity and venous engorgement of the posterior pole vasculature and is diagnosed by comparison with a standard photo&#173;graph. It implies vascular shunting through the new vessels and signifies severe disease (<span class="xref-figure">Fig 25-6</span>). <span class="italic">Pre–&#173;plus disease</span> refers to dilatation and tortuosity that are abnormal but less than that seen in the standard photo&#173;graph (<span class="xref-figure">Fig 25-7</span>).</p>
			<p class="body-text"><span class="italic">Aggressive posterior ROP</span> (AP-&#173;ROP; formerly known as <span class="italic">Rush disease</span>) is a severe form of ROP defined as zone I or posterior zone II disease, associated with plus disease involving all 4 quadrants of the posterior pole ret&#173;i&#173;nal vessels, shunt vessels, and flat neovascularization at the junction between vascularized and avascular ret&#173;ina. Without treatment, AP-&#173;ROP typically progresses quickly to stage 4 or 5 ROP (<span class="xref-figure">Fig 25-8</span>).</p>
			<p class="body-text">The Cryotherapy for Retinopathy of Prematurity (CRYO-&#173;ROP) trial defined <span class="italic">threshold</span> disease as 5 contiguous or 8 total clock-&#173;hours of stage 3 ROP in zone I or II in the presence of plus disease. The Early Treatment for Retinopathy of Prematurity (ETROP) trial defined <span class="italic">prethreshold disease</span> as all zone I and zone II ROP changes that do not meet threshold treatment criteria, except for zone II stage 1 and zone II stage 2 without plus disease. ETROP further divided prethreshold ROP into <span class="italic">type 1</span> and <span class="italic">type 2</span> disease to delineate which babies would benefit from treatment before the development of threshold disease (<span class="xref-table">&#173;Table&#160;25-3</span>).</p>
			<p class="reference--journal--single">International Committee for the Classification of Retinopathy of Prematurity. The Inter&#173;national Classification of Retinopathy of Prematurity revisited. <span class="italic">Arch Ophthalmol</span>. 2005;123(7):991–999.</p>
			<p class="h3">Risk &#173;factors for development of ROP</p>
			<p class="body-text--no-indent-">Premature birth (<span class="symbol">≤</span>30 weeks’ gestational age) and low birth weight (<span class="symbol">≤</span>1500&#160;g) are the most significant risk &#173;factors for development of ROP. Excessive administration of supplemental oxygen during the early postnatal period is also a risk &#173;factor for ROP development. Despite de&#173;cades of research, however, the ideal amount of oxygen required by a premature infant remains unknown. Low target ranges of oxygen saturation have been associated with an increased risk of death and disability. Low levels of serum IGF-&#173;I are associated with poor postnatal weight gain and more severe ROP. Numerous algorithms using postnatal weight gain to identify infants at risk for type 1 ROP have been developed and are &#173;under investigation. African American preterm infants are at lower risk for needing ROP treatment.</p>
			<p class="reference--journal--first">BOOST-&#173;II Australia and United Kingdom Collaborative Groups; Tarnow-&#173;Mordi W, Stenson&#160;B, Kirby A, et&#160;al. Outcomes of two &#173;trials of oxygen-&#173;saturation targets in preterm infants. <span class="italic">N&#160;Engl J Med</span>. 2016;374(8):749–760.</p>
			<p class="reference--journal--last">Saugstad OD, Aune&#160;D. Optimal oxygenation of extremely low birth weight infants: a meta-&#173;analysis and systematic review of the oxygen saturation target studies. <span class="italic">Neonatology</span>. 2014;105(1):55–63.</p>
			<p class="h3">Screening and diagnosis</p>
			<p class="body-text--no-indent-">Current guidelines from the American Acad&#173;emy of Pediatrics, American Acad&#173;emy of Ophthalmology, and American Association for Pediatric Ophthalmology and Strabismus recommend that infants with gestational age of 30 weeks or less, birth weight of 1500&#160;g or less, or a complicated clinical course be screened for ROP. The first examination should be performed at 4 weeks’ chronologic (postnatal) age or at a corrected gestational age of 31&#160;weeks, whichever is &#173;later (but not &#173;later than 6 weeks’ chronologic age). Current screening recommendations can be found on the website of the American Acad&#173;emy of Pediatrics (<a href="http://pediatrics.aappublications.org/content/131/1/189">http://&#173;pediatrics.&#173;aappublications.&#173;org/&#173;content/&#173;131/&#173;1/&#173;189</a>). In developing countries, ROP occurs in infants at an older gestational age and with a higher birth weight compared with infants in the United States. This suggests that screening criteria for ROP do not apply globally and should be modified in other regions of the world.</p>
			<p class="body-text">ROP examinations are performed &#173;after pharmacologic dilation of the pupils. Combination eyedrops of relatively low concentration (cyclopentolate 0.2% and phenylephrine 1%) are typically used. Sterile instruments should be used to examine the infant. A nurse should be pres&#173;ent for examinations in the neonatal intensive care unit &#173;because an infant may experience apnea and bradycardia during examination. If an examination must be postponed, the postponement and medical reason should be documented in the patient’s medical rec&#173;ord. Suggested intervals for follow-up ophthalmic examinations for ROP without plus disease are given in <span class="xref-table">&#173;Table&#160;25-4</span>; discontinuation of screening examinations is summarized in <span class="xref-table">&#173;Table&#160;25-5</span>. Most ROP regresses spontaneously via involution.</p>
			<p class="body-text">Diagnosis of ROP via digital ret&#173;i&#173;nal photography and telemedicine is &#173;under investigation. It is currently being used in developing countries and areas where ophthalmologists are not available to perform ROP examinations.</p>
			<p class="reference--journal--first">Fierson WM; American Acad&#173;emy of Pediatrics Section on Ophthalmology; American Acad&#173;emy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. <span class="italic">Pediatrics.</span> 2013;131(1):189–195.</p>
			<p class="reference--journal--last">Vinekar A, Jayadev C, Mangalesh S, Shetty B, Vidyasagar&#160;D. Role of tele-&#173;medicine in retinopathy of prematurity screening in rural outreach centers in India—&#173;a report of 20,214 imaging sessions in the KIDROP program. <span class="italic">Semin Fetal Neonatal Med.</span> 2015;20(5):335–345.</p>
			<p class="h3">Treatment</p>
			<p class="body-text--no-indent-">Approximately 10% of infants examined for ROP require treatment. Several multicenter ROP &#173;trials have been influential in guiding treatment of the disease. The initial ROP treatment study, CRYO-&#173;ROP, recommended treatment with cryotherapy when the disease reached a certain level of severity, termed <span class="italic">threshold.</span> Current treatment guidelines are based on results of the ETROP trial (see &#173;Table&#160;25-3 for ETROP classification), which found that earlier treatment in prethreshold eyes classified as type 1 resulted in better structural and visual outcomes than did conventional treatment. Panret&#173;i&#173;nal &#173;laser photocoagulation is performed to ablate the peripheral avascular ret&#173;ina (<span class="xref-figure">Fig 25-9</span>). Current guidelines strongly recommend treatment for any eye with type 1 ROP. Eyes with type 2 ROP should be closely observed for progression to type 1 disease (<span class="xref-video">Videos 25-1 through 25-4</span> show ROP progression and response to &#173;laser treatment).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"> <span class="QR-code-number">VIDEO 25-1</span> Stage 3 retinopathy of prematurity.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source ParaOverride-6"><span class="QR-code-source-italic CharOverride-1">Courtesy of Leslie&#160;D. MacKeen, BSc, and Anna&#160;L. Ells, MD, FRCS(C). Dynamic documentation <br />of the evolution of retinopathy of prematurity in video format.</span> <span class="CharOverride-2">J AAPOS.</span> <span class="QR-code-source-italic CharOverride-1">2008;12(4):349–351.</span></p>
			<p class="QR-code-text-last">Access all Section&#160;6 videos at <a href="http://www.aao.org/bcscvideo_section06">www.&#173;aao.&#173;org/&#173;bcscvideo_&#173;section06</a>.</p>
			<p class="body-text">AP-&#173;ROP typically occurs in zone I or posterior zone II, progresses rapidly, is often difficult to treat, and has a poor prognosis (see &#173;Table&#160;25-2 and <span class="xref-figure-local">Fig 25-8</span>). Another characteristic of AP-&#173;ROP is that it does not pro&#173;gress in the typical fashion (ie, through stages 1, 2, and 3), and stage 3 can often appear as flat neovascularization.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-7"> <span class="QR-code-number">VIDEO 25-2</span> Aggressive posterior retinopathy of prematurity <br />with &#173;laser treatment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto"><span class="QR-code-source-italic CharOverride-1">Courtesy of Leslie&#160;D. MacKeen, BSc, and Anna&#160;L. Ells, MD, FRCS(C). <br />Dynamic documentation of the evolution of retinopathy of prematurity in video format.</span> <br /><span class="CharOverride-2">J AAPOS.</span> <span class="QR-code-source-italic CharOverride-1">2008;12(4):349–351.</span></p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-8"> <span class="QR-code-number">VIDEO 25-3</span> Retinopathy of prematurity—&#173;the movie, 2.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADYAAAA2CAYAAACMRWrdAAAACXBIWXMAABcRAAAXEQHKJvM/AAAClUlEQVRoQ+2avcraUBjH3QvdeguC4AcKgouCi6DX4AWIQ8ChFLM0ixkrKF1Eurl0sHRy7E20XbwAoZChWEKhQ5p/eE+JebV/8x6THM+bwG8QT855fvl8Ts5T8Dyv8BQ2m824WCx6SWJZ1nsWxyVog2cjtl6vX7darR/1ev3IApOlWq26GMs0zTWLS1psuVy+ZQHdGsMwPrK4YovZtv1uMBh8FeAIskBuTaPR+BmOYTQafWZxUzEcLTZw2vhy31jcF/+YzWbz4XD4JYszxKjVar8Q23g8/hRbDDuyAbIGB/1qMdxTuPxUPFNRyuXyb8R67uHySAw3J+tQRXKxe+OiGDIK/+Vr3cO9dY7FYmEhftd1X5yI3atQFMdxXgViSGaBbO7XbreRtHqTyYS2TZLVavUGPgXW8Fr89x6uc2+/39O2aSAt1ul0kKTiGg/EDodD8DsM6yMJpMUQONtYH0mQihgu0zB+rkf7lSUVsejmvytpv7JkIubPpwI5gT/fouPEJROx6JbEA0YJMdM0MQX5xy3uQSXEopufGtFxGblYmmLRbbfb0ThysWvJxSQ2bcT8acfJCxyJNovjLsS0eSpiyhNOkrvdLh2XoYSYNimVbdsnE9Gn3EOMTMS0mbbgI0+YZrNJ+5UlFTHWRxJIi+GywuN5u90GEo7jBL/DsD6SQFpMoNznN6zMg0ql4rLG/6PX6wUZw3w+p22TZDqdfoCPvp+4hRhKDrCAhoVstrOKGA8LgMfj8eWJmEC7ZaRcTFGoGIpDUEeBkgPWWdaUSqU/iPVc3ccjMYF25RACFIdgR5QcsAHSBmcKsfX7/e+xxQSGbiVH2otF0aas79mIoY4C+RhW51lAsiChxVgiTYoDbXAJ1WuC/wLOZIWopgEC6wAAAABJRU5ErkJggg==" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto"><span class="QR-code-source-italic CharOverride-1">Courtesy of Anna&#160;L. Ells, MD, FRCS(C), and Leslie&#160;D. MacKeen, BSc. <br />Retinopathy of prematurity—&#173;the movie.</span> <span class="CharOverride-2">J AAPOS. </span><span class="QR-code-source-italic CharOverride-1">2004;8(4):389.</span></p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer007" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-9"> <span class="QR-code-number">VIDEO 25-4</span> Retinopathy of prematurity—&#173;the movie, 7.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-last-recto ParaOverride-10"><span class="QR-code-source-italic CharOverride-1">Courtesy of Anna&#160;L. Ells, MD, FRCS(C), and Leslie&#160;D. MacKeen, BSc. <br />Retinopathy of prematurity—&#173;the movie.</span> <span class="CharOverride-2">J AAPOS.</span> <span class="QR-code-source-italic CharOverride-1">2004;8(4):389.</span></p>
			<p class="body-text ParaOverride-11">The most recent treatment option for type 1 ROP is intravitreal injection of anti-&#173;VEGF agents bevacizumab and ranibizumab. The initial study of anti-&#173;VEGF agents for treatment of ROP, and the most influential, was Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-&#173;ROP), which found a significant benefit to structural outcome for zone I eyes that received intravitreal bevacizumab monotherapy compared with &#173;those that received &#173;laser treatment. Subsequent publications have documented that ROP may recur months &#173;after treatment with anti-&#173;VEGF agents; thus, prolonged surveillance and re-&#173;treatment may be necessary &#173;after intravitreal anti-&#173;VEGF injections. Anti-&#173;VEGF treatment should not be administered to infants who are unlikely to return for frequent follow-up examinations &#173;after they are discharged from the hospital.</p>
			<p class="body-text">&#173;There is concern that antiangiogenic drugs’ effects on the developing vasculature in other areas of the body may lead to adverse developmental outcomes. Abnormalities of ret&#173;i&#173;nal vasculature have been documented by fluorescein angiography years &#173;after anti-&#173;VEGF treatment. Further study is necessary to determine the long-&#173;term ocular and systemic effects of anti-&#173;VEGF agents used to treat ROP.</p>
			<p class="reference--journal--first">Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. <span class="italic">Arch Ophthalmol.</span> 2003;121(12):1684–1694.</p>
			<p class="reference--journal--mid">Early Treatment for Retinopathy of Prematurity Cooperative Group; Good WV, Hardy RJ, Dobson V, et&#160;al. Final visual acuity results in the Early Treatment for Retinopathy of Prematurity study. <span class="italic">Arch Ophthalmol.</span> 2010;128(6):663–671.</p>
			<p class="reference--journal--mid">Lepore D, Quinn GE, Molle F, et&#160;al. Intravitreal bevacizumab versus &#173;laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. <span class="italic">Ophthalmology</span>. 2014;121(11):2212–2219.</p>
			<p class="reference--journal--mid">Mintz-&#173;Hittner HA, Kennedy KA, Chuang AZ; BEAT-&#173;ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3<span class="symbol">+</span> retinopathy of prematurity. <span class="italic">N Engl J Med.</span> 2011;364(7):603–615.</p>
			<p class="reference--journal--mid">Morin J, Luu TM, Superstein R, et&#160;al; Canadian Neonatal Network and the Canadian Neonatal Follow-&#173;Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. <span class="italic">Pediatrics</span>. 2016;137(4). pii: e20153218.</p>
			<p class="h3">Sequelae and complications</p>
			<p class="body-text--no-indent-">One of the most common sequelae of significant ROP, &#173;whether treated or spontaneously regressed, is myopia, which may be severe. Also, premature infants with ROP, especially &#173;those who required treatment, are at higher risk for strabismus and amblyopia. Another recognized risk is glaucoma from crowding of the anterior chamber &#173;angle.</p>
			<p class="body-text">Vari&#173;ous sequelae due to ROP involution may be noted in the ret&#173;ina and its vasculature, including latticelike degeneration, failure of peripheral vascularization, and tortuous vessels. Dragging of the macula can occur, giving rise to pseudoexotropia as a result of a large positive &#173;angle kappa (<span class="xref-figure">Figs 25-10, 25-11</span>) (see <span class="xref-local">Chapter&#160;7</span> for a discussion of &#173;angle kappa). Eyes that have under&#173;gone treatment may also experience late ret&#173;i&#173;nal detachments at the border between treated and untreated ret&#173;ina. A child who has had ROP thus requires periodic ophthalmic examinations beyond the newborn period. Late changes associated with stage 5 ROP include cataract, glaucoma, and phthisis bulbi.</p>
			<p class="body-text">When &#173;laser treatment, cryotherapy, or intravitreal bevacizumab monotherapy has not prevented the progression of ROP to stage 4 or 5 (ret&#173;i&#173;nal detachment), scleral buckling and vitrectomy may be indicated. Anatomical success varies depending on many &#173;factors, but visual acuity results have been disappointing, particularly with stage 5 eyes.</p>
			<p class="body-text">Unfortunately, even with the current guidelines for screening and treatment, approximately 400–600 babies become legally blind &#173;because of ROP each year in the United States. Poor ROP outcomes may be perceived as medical malpractice and therefore pose a risk for litigation by patients or their families. The Ophthalmic Mutual Insurance Com&#173;pany (<a href="http://www.omic.com">www.&#173;omic.&#173;com</a>) offers numerous tools to help ophthalmologists limit their liability risk.</p>
			<p class="reference--journal--single">Repka MX, Tung B, Good WV, Capone A Jr, Shapiro MJ. Outcome of eyes developing ret&#173;i&#173;nal detachment during the Early Treatment for Retinopathy of Prematurity study. <span class="italic">Arch Ophthalmol.</span> 2011;129(9):1175–1179.</p>
			<p class="h2">Hereditary Ret&#173;i&#173;nal Disease</p>
			<p class="body-text--no-indent-">Nystagmus is the most common presenting sign of hereditary ret&#173;i&#173;nal disease. The onset of nystagmus typically occurs between 8 and 12 weeks of age and indicates limited visual potential if the cause is ret&#173;i&#173;nal disease (see <span class="xref-local">Chapter&#160;13</span>). In infantile nystagmus caused by certain forms of Leber congenital amaurosis, achromatopsia, or X-&#173;linked congenital stationary night blindness, the ret&#173;i&#173;nal appearance can be normal.</p>
			<p class="body-text">Nystagmus does not develop in all patients with hereditary ret&#173;i&#173;nal disease; for example, it may not develop in &#173;those with less severe ret&#173;i&#173;nal damage. Poor visual function or failed vision screening may be the presenting abnormality in older &#173;children with ret&#173;i&#173;nal disease. The paradoxical pupillary response (pupils that initially constrict in the dark rather than dilate) is common in hereditary ret&#173;i&#173;nal dystrophies (<span class="xref-table">&#173;Table&#160;25-6</span>).</p>
			<p class="body-text">Tests utilized to evaluate a patient with a pos&#173;si&#173;ble hereditary ret&#173;i&#173;nal disorder include electroretinography (ERG), electro-&#173;oculography (EOG), and optical coherence tomography (OCT), as well as color vision, visual field, and dark adaptation tests. Sedation or general anesthesia may be required in order to perform ERG or OCT in young &#173;children. &#173;Because significant ret&#173;i&#173;nal maturation occurs during the first few years of life, an ERG can appear subnormal in a healthy infant. To obtain more reliable results, ERG is performed &#173;after 6–10 months of age. Repeated ERG testing may be necessary to confirm abnormalities of phototransduction.</p>
			<p class="body-text">Hereditary ret&#173;i&#173;nal diseases with onset late in childhood are much like &#173;those in adulthood and are not covered &#173;here. See BCSC Section&#160;12, <span class="italic">Ret&#173;ina and Vitreous.</span></p>
			<p class="h3">Leber congenital amaurosis</p>
			<p class="body-text--no-indent-">Leber congenital amaurosis (LCA) is a group of hereditary (usually autosomal recessive) ret&#173;i&#173;nal dystrophies that affect both rod and cone photoreceptors. LCA is characterized by severe vision loss in infancy, nystagmus, poorly reactive pupils, and an extinguished ERG. Visual acuity typically ranges from 20/200 to bare light perception, but in some patients is not very low.</p>
			<p class="body-text">Ophthalmoscopic appearance varies greatly, depending on the genotype. It ranges from a normal appearance, particularly in infancy; to pigment clumping in the ret&#173;i&#173;nal pigment epithelium (RPE); to resemblance of classic retinitis pigmentosa, with bone spicules, attenuation of arterioles, and disc pallor. Other reported but less common fundus findings include extensive chorioret&#173;i&#173;nal atrophy, macular coloboma, white dots (similar to &#173;those seen in retinitis punctata albescens), and marbleized ret&#173;i&#173;nal appearance (<span class="xref-figure">Fig 25-12</span>). Histologic examination shows diffuse absence of photoreceptors.</p>
			<p class="body-text">Additional ocular manifestations include the oculodigital reflex (rubbing or poking the eye), photoaversion, cataracts, keratoconus, and keratoglobus. High refractive errors, usually high hyperopia, are common.</p>
			<p class="body-text">LCA-&#173;like phenotypes can be found in a number of systemic diseases, including peroxisomal disorders (Zellweger [cerebrohepatorenal] syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease) and the ciliopathies (Alstr<span class="accent">ö</span>m syndrome, Joubert syndrome, Senior-&#173;L<span class="accent">ø</span>ken syndrome, and Bardet-&#173;Biedl syndrome). The ciliopathies are a group of ge&#173;ne&#173;tic disorders in which the structure and/or function of the cilia is affected, manifesting in ce&#173;re&#173;bral anomalies and renal and ret&#173;i&#173;nal disease. Ret&#173;i&#173;nal involvement is common &#173;because the junction between inner and outer segments of the photoreceptor cell is modified nonmotile cilium (see <span class="xref-local">Chapter&#160;28</span>). Thus, ophthalmologists should be aware that an LCA-&#173;like phenotype may be the first sign of an undiagnosed systemic disease.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> An ERG is typically used to diagnose LCA. However, in a child with an obvious phenotype (oculodigital reflex, severely decreased vision at birth, and pigmentary retinopathy), ERG is not always necessary. Ge&#173;ne&#173;tic testing is impor&#173;tant and can be used to confirm the diagnosis, distinguish LCA from other ret&#173;i&#173;nal diseases, predict prognosis, and help with &#173;family planning. Molecular diagnosis of LCA is hindered by the fact that the disease is heterogeneous. &#173;At least 20 dif&#173;fer&#173;ent ge&#173;ne&#173;tic mutations are known to cause LCA; the most frequent involve <span class="italic">CEP290</span> (15%), <span class="italic">GUCY2D</span> (12%), and <span class="italic">CRB1</span> (10%), as well as <span class="italic">RPE65 </span>(6%).</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Gene therapy is available for biallelic <span class="italic">RPE65</span> disease. Studies have demonstrated improvement in subjective and objective vision &#173;after subret&#173;i&#173;nal injections of the gene promoter attached to an adenovirus viral particle, but it is unclear &#173;whether &#173;these results &#173;will be sustainable. Results seem most promising in young &#173;children.</p>
			<p class="reference--journal--first">Alkharashi M, Fulton AB. Available evidence on Leber congenital amaurosis and gene therapy. <span class="italic">Semin Ophthalmol</span>. 2017;32(1):14–21.</p>
			<p class="reference--journal--last">Weleber RG, Pennesi ME, Wilson DJ, et&#160;al. Results at 2&#160;years &#173;after gene therapy for RPE65-&#173;deficient Leber congenital amaurosis and severe early-&#173;childhood-&#173;onset ret&#173;i&#173;nal dystrophy. <span class="italic">Ophthalmology.</span> 2016;123(7):1606–1620.</p>
			<p class="h3">Achromatopsia</p>
			<p class="body-text--no-indent-">Complete achromatopsia, also known as <span class="italic">rod monochromatism,</span> is an autosomal recessive congenital disorder of the cone photoreceptors in which patients have no color vision, poor central vision, nystagmus, and photophobia. &#173;These patients see the world in shades of gray. Hemeralopia, the inability to see clearly in bright light, occurs in &#173;these patients.</p>
			<p class="body-text">Findings on ret&#173;i&#173;nal examination are usually normal, with the pos&#173;si&#173;ble exception of a poor or absent foveal reflex. Although achromatopsia was initially thought to be a stationary disorder, results of recent studies have shown deterioration of visual acuity, macular appearance, and cone function on ERG.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> Results of color vision testing are markedly abnormal. The ERG is subnormal, showing extinguished cone or photopic responses but normal or nearly normal rod responses. Several recessive gene mutations have been identified as the cause of achromatopsia, including mutations in <span class="italic">CNGA3, CNGB3</span> (most common), <span class="italic">GNAT2, PDE6C,</span> and <span class="italic">PDE6H.</span></p>
			<p class="body-text">Other cone dystrophies causing early-&#173;onset visual impairment and nystagmus include <span class="italic">incomplete achromatopsia,</span> which is an autosomal recessive condition, and <span class="italic">blue-&#173;cone monochromatism,</span> which is an X-&#173;linked disorder<span class="italic">.</span> In both disorders, patients usually have better vision than do &#173;those with complete achromatopsia. In incomplete achromatopsia, some residual cone function is observed on ERG testing. In blue-&#173;cone monochromatism, the blue (short-&#173;wavelength) cones show normal function on specialized ERG testing, but the photopic response is usually extinguished.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Glasses with dark lenses or red lenses that exclude short wavelengths may help. Gene therapy has been used in animal models.</p>
			<p class="h3 ParaOverride-5">Congenital stationary night blindness</p>
			<p class="body-text--no-indent-"><span class="italic">Congenital stationary night blindness (CSNB)</span> refers to a group of nonprogressive ret&#173;i&#173;nal disorders characterized predominantly by abnormal function of the rod system. The condition may be X-&#173;linked (the most common form), autosomal recessive, or autosomal dominant.</p>
			<p class="body-text">&#173;Children with CSNB, especially the autosomal recessive and X-&#173;linked forms, usually pres&#173;ent in early infancy with nystagmus and a normal fundus appearance. &#173;These forms are often also associated with myopia and decreased visual acuity of roughly 20/200. However, the range of vision in &#173;these patients is wide, and occasionally, patients have normal vision. The ret&#173;ina usually appears normal, but the optic nerve may show myopic tilt and temporal pallor.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> An ERG or ge&#173;ne&#173;tic testing is necessary for diagnosis. The most common ERG pattern seen in CSNB is the “negative” dark-&#173;adapted ERG: a large a-&#173;wave and a reduced-&#173;amplitude (negative) b-&#173;wave. Dark adaptation is abnormal in all patients with CSNB. Infants with CSNB may have a flat ERG &#173;until approximately 6 months of age, when it converts to the classic negative configuration.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Bright illumination should be used for visual tasks and refractive errors corrected.</p>
			<p class="h3 ParaOverride-5">Foveal hypoplasia</p>
			<p class="body-text--no-indent-">Foveal hypoplasia, or incomplete development of the fovea, is another cause of nystagmus in early infancy. Although this condition is most often associated with albinism or aniridia, it may also be isolated or familial and may be related to a defect in the <span class="italic">PAX6</span> gene. On ophthalmoscopic examination, the foveal reflex is poor or absent, and the macula exhibits hypoplasia to varying degrees, which can also be seen in patients with complete achromatopsia.</p>
			<p class="reference--journal--single">Al-&#173;Saleh AA, Hellani A, Abu-&#173;Amero KK. Isolated foveal hypoplasia: report of a new case and detailed ge&#173;ne&#173;tic investigation. <span class="italic">Int Ophthalmol.</span> 2011;31(2):117–120.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> Fundus examination showing foveal hypoplasia is diagnostic. OCT may be useful.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> No treatment is currently available.</p>
			<p class="h3 ParaOverride-5">Aicardi syndrome</p>
			<p class="body-text--no-indent-">Aicardi syndrome is a presumed X-&#173;linked autosomal dominant disorder characterized by the clinical triad of widespread round or oval depigmented chorioret&#173;i&#173;nal lacunae (<span class="xref-figure">Fig&#160;</span><span class="xref-figure">25-13</span>), infantile spasms, and agenesis of the corpus callosum. Chorioret&#173;i&#173;nal lacunae have been shown to occur in 88% of patients; optic nerve abnormalities, in 81%. Colobomas, per&#173;sis&#173;tent pupillary membranes, and microphthalmia may also occur. Aicardi syndrome is typically lethal in males.</p>
			<p class="reference--journal--single">Fruhman G, Eble TN, Gambhir N, Sutton VR, Van den Veyver IB, Lewis RA. Ophthalmologic findings in Aicardi syndrome. <span class="italic">J AAPOS.</span> 2012;16(3):238–241.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> The clinical picture provides the foundation for diagnosis.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> No treatment is currently available.</p>
			<p class="h2">Hereditary Macular Dystrophies</p>
			<p class="body-text--no-indent-">Macular abnormalities are seen in a number of hereditary disorders. The abnormality can be associated with a hereditary systemic disease (eg, the cherry-&#173;red spot in GM<span class="subscript CharOverride-3">2</span> gangliosidosis type I) or can reflect a primary ret&#173;i&#173;nal disorder, such as Stargardt disease or Best disease. Only primary ret&#173;i&#173;nal disorders are discussed &#173;here.</p>
			<p class="h3">Stargardt disease</p>
			<p class="body-text--no-indent-">Stargardt disease (juvenile macular degeneration) is the most common hereditary macular dystrophy. Inheritance is usually autosomal recessive; in rare cases, it is autosomal dominant. Most cases are caused by mutations in the retina-&#173;specific adenosine triphosphate–&#173;binding transporter gene <span class="italic">(ABCA4).</span> &#173;Children with Stargardt disease usually pres&#173;ent between ages 8 and 15&#160;years with a decrease in vision, photophobia, or color vision abnormalities. The condition is bilateral, symmetric, and progressive; visual acuity levels off at approximately 20/50–20/200.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> The disease often progresses through stages. Initially, the fundus appears normal even when vision is decreased, and the condition may be misdiagnosed as functional vision loss. The first ophthalmoscopic changes observed are loss of foveal reflex, followed by development of a characteristic macular bull’s-&#173;eye atrophy surrounded by round or pisciform yellowish flecks, which develop in the posterior pole at the level of the RPE. If the flecks are scattered throughout the fundus, the condition may be referred to as <span class="italic">fundus flavimaculatus.</span> Before the flecks develop, the macula often appears atrophic due to diseased RPE, inducing a peculiar light-&#173;reflecting quality resembling that of beaten bronze (<span class="xref-figure">Figs 25-14, 25-15</span>).</p>
			<p class="body-text">The “dark choroid” sign on fluorescein angiography is distinctive but is not pres&#173;ent in all patients. This phenomenon is due to the accumulation of lipofuscin within the RPE, which blocks the choroidal fluorescence. Fluorescein angiography has been largely replaced by fundus autofluorescence (FAF) testing for the confirmation of Stargardt disease. FAF reveals both increased autofluorescence due to lipofuscin accumulation in the RPE and reduced autofluorescence in areas of RPE atrophy and photoreceptor loss (see Fig <span class="xref-figure">25-15C, </span><span class="xref-figure">D</span>). OCT imaging of the macula can reveal lipofuscin accumulation in the RPE and photoreceptor loss.</p>
			<p class="body-text">Results of visual field testing may be normal in the early stages of the disease. Disease progression &#173;will result in a central scotoma.</p>
			<p class="body-text">ERG results are often normal in the early stages of Stargardt disease. Stargardt &#173;disease can be associated with a progressive cone–&#173;rod dystrophy that has a much worse visual prognosis and an extinguished ERG.</p>
			<p class="body-text">Detection of <span class="italic">ABCA4</span> mutations via ge&#173;ne&#173;tic testing may be diagnostic.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Gene therapy for Stargardt disease has been used in animal models and is being studied in phase 1/2a clinical &#173;trials in &#173;humans.</p>
			<p class="reference--journal--single">Han Z, Conley SM, Naash MI. Gene therapy for Stargardt disease associated with <span class="italic">ABCA4</span> gene<span class="italic">. Adv Exp Med Biol</span>. 2014;801:719–724.</p>
			<p class="h3">Best disease</p>
			<p class="body-text--no-indent-">Classic Best disease, or <span class="italic">juvenile-&#173;onset vitelliform macular dystrophy (VMD),</span> is an autosomal dominant ret&#173;i&#173;nal disorder with variable penetrance and expressivity. The condition is caused by mutations in the <span class="italic">BEST1</span> gene on chromosome 11, which encodes for the protein bestrophin. Patients usually pres&#173;ent asymptomatically in childhood with the classic ret&#173;i&#173;nal appearance, or &#173;later in life with decrease in vision.</p>
			<p class="body-text">Over the last de&#173;cade, a rare, distinct phenotype—&#173;<span class="italic">autosomal dominant vitreoretinochoroidopathy (ADVIRC)—&#173;</span>has been recognized. ADVIRC results from exon-&#173;skipping mutation in <span class="italic">BEST1</span>. A separate, distinct phenotype caused by biallelic null mutations in <span class="italic">BEST1</span> also exists<span class="italic">.</span> The vari&#173;ous phenotypes caused by heterozygous or biallelic mutations of <span class="italic">BEST1</span> are collectively termed <span class="italic">bestrophinopathies.</span></p>
			<p class="reference--journal--single">Pasquay C, Wang LF, Lorenz B, Preising MN. Bestrophin 1—&#173;phenotypes and functional aspects in bestrophinopathies. <span class="italic">Ophthalmic Genet</span>. 2015;36(3):193–212.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> The ret&#173;ina may appear normal at first, but between 4 and 10&#160;years of age, the “egg yolk,” or vitelliform, stage begins (<span class="xref-figure">Fig 25-16</span>). A yellow-&#173;orange cystlike structure is seen, usually in the macula; however, the lesion may occur elsewhere, and occasionally &#173;there are multiple lesions. The lesions are usually 1.5–5.0 disc dia&#173;meters in size. The egg yolk–&#173;like appearance is associated with good central vision.</p>
			<p class="body-text">With time, the cystic material may become granular, giving rise to the “scrambled egg” stage. At this stage, central vision usually remains good, with visual acuity roughly 20/30. The cyst may rupture and become partially resorbed; a pseudohypopyon may form from cystic contents. <span class="italic">Choroidal neovascular membranes (CNVMs)</span> and <span class="italic">pigment epithelial detachments (PEDs)</span> develop in 20% of patients (<span class="xref-figure">Fig 25-17A</span>). Subret&#173;i&#173;nal hemorrhage may occur, and visual acuity may deteriorate to 20/100 or worse. FAF reveals central macular hyperautofluorescence due to vitelliform material (<span class="xref-figure">Fig 25-17B</span>). Fluorescein angiography reveals central macular hyperfluorescence due to staining of the vitelliform material as well as late leakage from a CNVM, if pres&#173;ent (Fig 25-17C, D). Spectral-&#173;domain OCT (SD-&#173;OCT) imaging can further illustrate the central macular abnormalities (Fig 25-17E, F).</p>
			<p class="body-text">The EOG is usually abnormal in affected patients and carriers. This disorder is one of the few in which the EOG is abnormal and the ERG is normal. <span class="italic">BEST1</span> gene mutations are found in 60%–83% of affected patients. Carriers can be identified by the presence of an abnormal EOG with a normal ret&#173;ina or a <span class="italic">BEST1</span> gene mutation.</p>
			<p class="reference--journal--single">Meunier I, S<span class="accent">é</span>n<span class="accent">é</span>chal A, Dhaenens CM, et&#160;al. Systematic screening for <span class="italic">BEST1</span> and <span class="italic">PRPH2</span> in juvenile and adult vitelliform macular dystrophies: a rationale for molecular analy&#173;sis. <span class="italic">Ophthalmology.</span> 2011;118(6):1130–1136.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> No treatment is indicated &#173;unless subret&#173;i&#173;nal neovascularization occurs.</p>
			<p class="h2">Hereditary Vitreoretinopathies</p>
			<p class="body-text--no-indent-">Hereditary vitreoretinopathies include a broad range of disease entities. The ones discussed &#173;here characteristically pres&#173;ent in childhood.</p>
			<p class="h3">Juvenile retinoschisis</p>
			<p class="body-text--no-indent-">Juvenile retinoschisis (splitting of the ret&#173;ina) is an X-&#173;linked disease caused by mutations in the <span class="italic">RS1</span> gene, which encodes for the ret&#173;i&#173;nal protein retinoschisin, an adhesion protein that is believed to be essential to the health of M<span class="accent">ü</span>ller cells. Affected males usually pres&#173;ent in early childhood with decreased vision. Visual acuity varies but usually deteriorates to roughly 20/200.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> Foveal retinoschisis is pres&#173;ent in almost all cases; peripheral retinoschisis, in approximately 50% of patients. The fovea has a stellate or spokelike configuration that may resemble cystoid macular edema; it becomes less distinct over time. SD-&#173;OCT shows schisis spaces in the &#173;middle layers of the macula (<span class="xref-figure">Fig 25-18A</span>). Vitreous veils or strands are common, and vitreal syneresis, or liquefaction, is prominent. Complications include vitreous hemorrhage and vari&#173;ous types of ret&#173;i&#173;nal detachment (Figs 25-18B, <span class="xref-figure">25-19</span>). The ERG shows a reduction of the scotopic b-&#173;wave with preservation of the a-&#173;wave.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Contact sports should be avoided &#173;because the ret&#173;ina in affected eyes is more susceptible to trauma. Gene replacement has shown some success in mouse models. Use of carbonic anhydrase inhibitors to treat cystic macular lesions is &#173;under investigation.</p>
			<p class="reference--journal--single">Verbakel SK, van de Ven JP, Le Blanc LM, et&#160;al. Carbonic anhydrase inhibitors for the treatment of cystic macular lesions in &#173;children with X-&#173;linked juvenile retinoschisis. <span class="italic">Invest Ophthalmol Vis Sci</span>. 2016;57(13):5143–5147.</p>
			<p class="h3">Stickler syndrome</p>
			<p class="body-text--no-indent-">Stickler syndrome is a group of connective tissue disorders with variable phenotypic expression. The most common type of Stickler syndrome is autosomal dominant, has ocular and systemic findings, and is caused by a mutation in <span class="italic">COL2A1,</span> the gene that encodes for type II procollagen. Some mutations in the gene cause an ocular-&#173;only phenotype.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> The diagnosis is made based on the clinical features as well as the results of ge&#173;ne&#173;tic testing. Common ocular abnormalities include an optically empty vitreous due to vitreous liquefaction, high myopia, lattice degeneration, and proliferative vitreoretinopathy. In addition, &#173;there is a high incidence of ret&#173;i&#173;nal detachment secondary to ret&#173;i&#173;nal breaks. Anterior chamber &#173;angle anomalies, ectopia lentis, cataracts, ptosis, and strabismus are less common.</p>
			<p class="body-text">Characteristic systemic abnormalities are a flat midface, progressive hearing loss, cleft palate, Pierre Robin sequence, mitral valve prolapse, and progressive arthropathy with spondyloepiphyseal dysplasia. Although the arthropathy may not be symptomatic initially, &#173;children with Stickler syndrome often show radiographic abnormalities of the long bones and joints, and associated symptoms develop.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> The ret&#173;i&#173;nal detachments are often difficult to repair &#173;because &#173;these patients may have large ret&#173;i&#173;nal breaks posteriorly and the incidence of proliferative vitreoretinopathy is high. The incidence of vitreous loss during cataract surgery is high, as is the rate of subsequent ret&#173;i&#173;nal detachment. Ret&#173;i&#173;nal folds and breaks should be treated before cataract extraction. Prophylactic retinopexy may be appropriate in certain patients.</p>
			<p class="reference--journal--single">Fincham GS, Pasea L, Carroll C, et&#160;al. Prevention of ret&#173;i&#173;nal detachment in Stickler syndrome: the Cambridge prophylactic cryotherapy protocol. <span class="italic">Ophthalmology</span>. 2014;121(8):1588–1597.</p>
			<p class="h3">Knobloch syndrome</p>
			<p class="body-text--no-indent-">Knobloch syndrome is a vitreoretinopathy caused by biallelic mutations in <span class="italic">COL18A1.</span> It is classically defined by the triad of occipital encephalocele, high myopia, and predisposition to ret&#173;i&#173;nal detachment.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> The ocular phenotype is characterized by a distinct vitreoret&#173;i&#173;nal degeneration—&#173;very severe RPE atrophic changes with prominent choroidal vessels (<span class="xref-figure">Fig 25-20A</span>) out of proportion to the degree of myopia, macular atrophic lesions with or without a “punched-&#173;out” appearance, and white fibrillar vitreous condensations. &#173;These eyes have a strong predisposition to spontaneous ret&#173;i&#173;nal detachment. Smooth (cryptless) irides are universal in affected eyes (<span class="xref-figure">Fig 25-20B</span>); ectopia lentis is an occasional finding. Taken together, &#173;these ocular findings are pathognomonic for biallelic <span class="italic">COL18A1</span> mutations.</p>
			<p class="body-text">ERG shows cone–&#173;rod dysfunction. Pigment dispersion glaucoma has been reported in 2 patients.</p>
			<p class="body-text">Systemic manifestations are variable and not always pres&#173;ent; they include occipital abnormalities (<span class="xref-figure">Fig 25-20C</span>) (ranging from scalp abnormalities to encephalocele), congenital renal malformations, developmental delay, seizures, and heterotopic gray &#173;matter.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Therapy is based on disease manifestations.</p>
			<p class="reference--journal--single">Khan AO, Aldahmesh MA, Mohamed JY, Al-&#173;Mesfer S, Alkuraya FS. The distinct ophthalmic phenotype of Knobloch syndrome in &#173;children. <span class="italic">Br J Ophthalmol.</span> 2012;96(6):890–895.</p>
			<p class="h3">Norrie disease</p>
			<p class="body-text--no-indent-">Norrie disease is an X-&#173;linked recessive disorder of ret&#173;i&#173;nal dysplasia caused by a mutation in the <span class="italic">NDP</span> gene, which encodes for the protein norrin. Affected boys are typically born blind and have varying degrees of hearing impairment and intellectual disability.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> The condition is characterized by a distinctive ret&#173;i&#173;nal appearance: a globular, severely dystrophic ret&#173;ina with pigmentary changes in the avascular periphery. During the first few days or weeks of life, a bilateral, yellowish ret&#173;i&#173;nal detachment appears, followed by a whiter mass &#173;behind the clear lens. Over time, the lenses, and &#173;later the cornea, opacify; phthisis bulbi may ensue by age 10&#160;years or earlier. Female carriers show peripheral ret&#173;i&#173;nal abnormalities.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> No treatment exists.</p>
			<p class="h3">Familial exudative vitreoretinopathy</p>
			<p class="body-text--no-indent-">Familial exudative vitreoretinopathy (FEVR) is a disease of abnormal ret&#173;i&#173;nal vascularization similar to that seen in ROP (discussed earlier in the chapter). &#173;There is failure of the peripheral ret&#173;ina to vascularize. FEVR is typically autosomal dominant, but autosomal recessive and X-&#173;linked forms exist as well, the latter resulting from mutations in the same gene involved in Norrie disease <span class="italic">(NDP).</span></p>
			<p class="reference--journal--single">Khan AO, Lenzner S, Bolz HJ. A &#173;family harboring homozygous <span class="italic">FZD4</span> deletion supports the existence of recessive <span class="italic">FZD4</span>-&#173;related familial exudative vitreoretinopathy. <span class="italic">Ophthalmic Genet</span>. 2017;38(4):380–382.</p>
			<p class="h4-text"><span class="h4-head">Diagnosis</span> Posterior pole findings in FEVR include ret&#173;i&#173;nal traction, folds, breaks, and detachment secondary to vitreous traction (<span class="xref-figure">Fig 25-21A</span>). Posterior vitreous detachment and thick peripheral intraret&#173;i&#173;nal and subret&#173;i&#173;nal exudates may develop (<span class="xref-figure">Fig 25-21B</span>). The disease is bilateral and can mimic ROP but affects infants born at full term. Fluorescein angiography shows areas of ret&#173;i&#173;nal nonperfusion and neovascularization (<span class="xref-figure">Fig 25-21C</span>). Examination of &#173;family members is impor&#173;tant in the diagnosis of FEVR. Affected &#173;family members can show marked variation in severity, from minimal straightening of ret&#173;i&#173;nal vessels and peripheral nonperfusion to total ret&#173;i&#173;nal detachment.</p>
			<p class="h4-text"><span class="h4-head">Treatment</span> Cryopexy, photocoagulation, vitrectomy, and cataract surgery have been used to manage patients with this disorder.</p>
			</div>
			<p class="h1">Infectious Diseases</p>
			<div id="Chapt25_Top2">
			<p class="h2-h1">Herpes Simplex Virus and Cytomegalovirus</p>
			<p class="body-text--no-indent-">Herpes simplex virus and cytomegalovirus are discussed in <span class="xref-local">Chapter&#160;28</span>.</p>
			<p class="h2">&#173;Human Immunodeficiency Virus</p>
			<p class="body-text--no-indent-">The ocular complications of HIV infection have been noted only rarely since the advent of potent antiretroviral therapy. Such complications typically occur only in &#173;children with advanced HIV infection who are severely immunocompromised. For more information, see BCSC Section&#160;9, <span class="italic">Intraocular Inflammation and Uveitis,</span> and Section&#160;12, <span class="italic">Ret&#173;</span><span class="italic">ina and Vitreous.</span></p>
			</div>
			<p class="h1">Tumors</p>
			<div id="Chapt25_Top3">
			<p class="h2-h1">Choroidal and Retinal Pigment Epithelial Lesions</p>
			<p class="body-text--no-indent-">A pigmented fundus lesion in a child is usually benign. Flat choroidal nevi are common and are not a cause for concern. Malignant melanoma of the choroid is extremely rare in &#173;children. Choroidal osteoma is a benign bony tumor of the uveal tract that may occur in childhood, usually presenting with decreased vision. Diffuse hemangioma of the choroid associated with Sturge-&#173;Weber syndrome is discussed in <span class="xref-local">Chapter&#160;28</span>. Patients with neurofibromatosis type 1 often have flat, tan-&#173;colored spots in the choroid (see <span class="xref-local">Chapter&#160;28</span>).</p>
			<p class="body-text"><span class="italic">Congenital hypertrophy of the ret&#173;i&#173;nal pigment epithelium (CHRPE)</span> is a sharply demarcated, flat, hyperpigmented lesion that may be isolated or multifocal (<span class="xref-figure">Fig 25-22</span>). Such lesions are sometimes grouped, in which case they are also called <span class="italic">bear tracks.</span></p>
			<p class="body-text">Pigmented lesions similar to CHRPE have been associated with Gardner syndrome, an autosomal dominant condition caused by a mutation in the <span class="italic">APC</span> gene, located at 5q22.2. Patients with Gardner syndrome have many polyps of the colon, which carry a very high risk for malignant transformation. Affected individuals often require a colectomy in early adulthood to prevent cancer. They may also have skeletal hamartomas and vari&#173;ous other soft-&#173;tissue tumors. The pigmented ret&#173;i&#173;nal lesions associated with Gardner syndrome are dif&#173;fer&#173;ent from CHRPE in that they are typically multiple, bilateral, and dispersed; in addition, they often have a surrounding halo and tail of depigmentation that is oriented radially and directed &#173;toward the optic nerve (<span class="xref-figure">Fig 25-23</span>).</p>
			<p class="body-text"><span class="italic">Combined hamartoma of the ret&#173;ina and RPE</span> is an ill-&#173;defined, elevated, variably pigmented tumor that may be juxtapapillary or located in the ret&#173;i&#173;nal periphery. The tumor is often minimally elevated; ret&#173;i&#173;nal traction and tortuous ret&#173;i&#173;nal vessels are often pres&#173;ent. In peripheral tumors, dragging of the ret&#173;i&#173;nal vessels is a prominent feature. The tumors have a variable composition of glial tissue and RPE. This condition can be associated with neurofibromatosis (type 1 or 2), incontinentia pigmenti, X-&#173;linked retinoschisis, and facial hemangiomas. Bilateral lesions in a child should raise suspicion for neurofibromatosis type 2.</p>
			<p class="reference--journal--single">Traboulsi EI. Ocular manifestations of familial adenomatous polyposis (Gardner syndrome). <span class="italic">Ophthalmol Clin North Am</span>. 2005;18(1):163–166.</p>
			<p class="h2">Retinoblastoma</p>
			<p class="body-text--no-indent-">Retinoblastoma is the most common malignant intraocular tumor of childhood and one of the most common pediatric solid tumors, with an incidence of 1:14,000–1:20,000 live births. It is equally common in both sexes and has no racial predilection. Retinoblastoma is a neuroblastic tumor and is therefore biologically similar to neuroblastoma and medulloblastoma. The tumor can be unilateral or bilateral; 30%–40% of cases are bilateral. In familial and bilateral cases, retinoblastoma is typically diagnosed during the first year of life; in sporadic unilateral cases, between 1 and 3&#160;years of age. Approximately 90% of cases are diagnosed before 3&#160;years of age; onset &#173;later than age 5&#160;years is rare but can occur.</p>
			<p class="body-text">The most common initial sign is leukocoria (white pupillary reflex), which is usually first noticed by the &#173;family and described as a glow, glint, or cat’s-&#173;eye appearance (<span class="xref-figure">Fig 25-</span><span class="xref-figure">24</span>). The differential diagnosis of leukocoria is presented in <span class="xref-table">&#173;Table&#160;25-7</span>. Approximately 25% of cases pres&#173;ent with strabismus (esotropia or exotropia). Less common pre&#173;sen&#173;ta&#173;tions include vitreous hemorrhage, hyphema, ocular or periocular inflammation, glaucoma, proptosis, and pseudohypopyon.</p>
			<p class="h3">Diagnosis</p>
			<p class="body-text--no-indent-">Diagnosis of retinoblastoma is usually based on its ophthalmoscopic appearance. Intraocular retinoblastoma can exhibit a variety of growth patterns. With endophytic growth, it appears as a white to cream-&#173;colored mass that breaks through the internal limiting membrane (<span class="xref-figure">Fig 25-25</span>). Endophytic retinoblastoma is sometimes associated with vitreous seeding, in which individual cells or fragments of tumor tissue become separated from the main mass, as shown in <span class="xref-figure">Figure&#160;25-26</span>. Vitreous seeds may be few and localized or so extensive that the clinical picture resembles endophthalmitis. Occasionally, malignant cells enter the anterior chamber and form a pseudohypopyon.</p>
			<p class="body-text">Exophytic tumors are usually yellow-&#173;white and occur in the subret&#173;i&#173;nal space; the overlying ret&#173;i&#173;nal vessels are commonly larger in caliber and more tortuous (<span class="xref-figure">Fig 25-27</span>). Exophytic retinoblastoma growth is often associated with subret&#173;i&#173;nal fluid accumulation, which can obscure the tumor and closely mimic the appearance of an exudative ret&#173;i&#173;nal detachment suggestive of advanced Coats disease. Retinoblastoma cells have the potential to implant on previously uninvolved ret&#173;i&#173;nal tissue and grow, thereby creating an impression of multicentricity in an eye with only a single primary tumor.</p>
			<p class="body-text">Large tumors often show signs of both endophytic and exophytic growth. Small retinoblastoma lesions appear as a grayish mass and are frequently confined between the internal and external limiting membranes. A third pattern, diffuse infiltrative retinoblastoma, is usually unilateral and nonhereditary. It is found in &#173;children older than 5&#160;years. The tumor pres&#173;ents with conjunctival injection, anterior chamber seeds, pseudohypopyon, large clumps of vitreous cells, and ret&#173;i&#173;nal infiltration of tumor. &#173;Because no distinct tumor mass is pres&#173;ent, diagnostic confusion with inflammatory conditions is common.</p>
			<p class="body-text">Spontaneous regression of retinoblastoma is pos&#173;si&#173;ble. It can be asymptomatic, resulting in the development of a benign retinocytoma, or it can be associated with inflammation and, ultimately, phthisis bulbi. In &#173;either case, the ge&#173;ne&#173;tic implications are the same as for an individual with an active retinoblastoma.</p>
			<p class="body-text">The most common ret&#173;i&#173;nal lesion simulating retinoblastoma is seen in Coats disease. The presence of crystalline material, extensive subret&#173;i&#173;nal fluid, and peripheral vascular abnormalities—&#173;combined with the absence of calcium—&#173;suggests Coats disease. <span class="italic">Astrocytic hamartomas</span> and <span class="italic">hemangioblastomas</span> are benign ret&#173;i&#173;nal tumors that may simulate the appearance of small retinoblastomas. Both are usually associated with neuro-&#173;oculocutaneous syndromes (see <span class="xref-local">Chapter&#160;28</span>).</p>
			<p class="body-text">Evaluation of a patient with presumed retinoblastoma requires imaging of the head and orbits, which can confirm the diagnosis and assess for extraocular extension and intracranial disease. Computed tomography is discouraged &#173;because of the pos&#173;si&#173;ble increased risk of secondary tumors due to radiation exposure. Magnetic resonance imaging and ultrasonography are recommended. More invasive tests are reserved for aty&#173;pi&#173;cal cases. Aspiration of ocular fluids for diagnostic testing should be performed only &#173;under the most unusual circumstances &#173;because such procedures can disseminate malignant cells. Recently, however, it was demonstrated that cell-&#173;free tumor-&#173;derived DNA may be obtained from aqueous humor.</p>
			<p class="body-text">The characteristic histologic features of retinoblastoma include Flexner-&#173;Wintersteiner rosettes, which are usually pres&#173;ent, and fleurettes, which are less common. Both represent limited degrees of ret&#173;i&#173;nal cellular differentiation. Homer Wright rosettes are also frequently pres&#173;ent but are less specific for retinoblastoma &#173;because they are common in other neuroblastic tumors. Calcification of varying extent is usually pres&#173;ent.</p>
			<p class="reference--journal--first">Berry JL, Xu L, Murphree AL, et&#160;al. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. <span class="italic">JAMA Ophthalmol.</span> 2017;135(11):1221–1230.</p>
			<p class="reference--journal--last">de Graaf P, G<span class="accent">ö</span>ricke S, Rodjan F, et&#160;al; Eu&#173;ro&#173;pean Retinoblastoma Imaging Collaboration. Guidelines for imaging retinoblastoma: imaging princi&#173;ples and MRI standardization. <span class="italic">Pediatr Radiol.</span> 2012;42(1):2–14.</p>
			<p class="h4-text"><span class="h4-head">Genetics</span> The retinoblastoma gene <span class="italic">(RB1)</span> maps to a locus within the q14 band of chromosome 13 and codes for a protein, pRB, that suppresses tumor formation. For retinoblastoma to occur, both <span class="italic">RB1</span> genes must have a mutation. Approximately 60% of retinoblastoma cases arise from somatic nonhereditary mutations of both alleles of <span class="italic">RB1</span> in a ret&#173;i&#173;nal cell. &#173;These mutations generally result in unifocal and unilateral tumors. In the other 40% of patients, a germline mutation in 1 of the 2 alleles of <span class="italic">RB1</span> &#173;either is inherited from an affected parent (10% of all retinoblastoma cases) or occurs spontaneously in 1 of the gametes. A second somatic mutation in a ret&#173;i&#173;nal cell is all that is necessary for retinoblastoma to develop; such cases are often multicentric and bilateral.</p>
			<p class="body-text">Ge&#173;ne&#173;tic counseling for families of retinoblastoma patients is complex (<span class="xref-table">&#173;Table&#160;25-8</span>). Both parents and all siblings should be examined. In approximately 1% of cases, a parent may be found to have an unsuspected fundus lesion that represents a spontaneously regressed retinoblastoma (retinocytoma).</p>
			<p class="body-text">Ge&#173;ne&#173;tic testing for retinoblastoma is impor&#173;tant for determining the risk of subsequent cancers (both retinoblastoma and other primary neoplasms) in the affected child and the risk of retinoblastoma in other &#173;family members. The probability of detecting the <span class="italic">RB1</span> gene depends on many &#173;factors, including the capabilities of the molecular diagnostic laboratory, the presence of tumor tissue, and the ability to test other affected &#173;family members.</p>
			<p class="body-text">Preimplantation ge&#173;ne&#173;tic testing can be performed, and in vitro fertilization techniques have been used successfully to select embryos that are &#173;free from the germinal <span class="italic">RB1</span> mutation.</p>
			<p class="reference--journal--last ParaOverride-12">Dhar SU, Chintagumpala M, Noll C, Ch<span class="accent">é</span>vez-&#173;Barrios P, Paysse EA, Plon SE. Outcomes of integrating ge&#173;ne&#173;tics in management of patients with retinoblastoma. <span class="italic">Arch Ophthalmol.</span> 2011;129(11):1428–1434.</p>
			<p class="h4-text ParaOverride-12"><span class="h4-head">Classification of retinoblastoma</span> The International Classification of Retinoblastoma (ICRB; <span class="xref-table">&#173;Table&#160;25-9</span>) is useful for predicting the success of chemoreduction and has superseded the Reese-&#173;Ellsworth classification, which was originally developed to predict globe salvage &#173;after external-&#173;beam radiotherapy. The American Joint Committee on Cancer (AJCC) also has a staging system for retinoblastoma that addresses both intraocular and extraocular disease (see BCSC Section&#160;4, <span class="italic">Ophthalmic Pathology and Intraocular Tumors</span>).</p>
			<p class="reference--journal--single">Shields CL, Mashayekhi A, Au AK, et&#160;al. The International Classification of Retinoblastoma predicts chemoreduction success. <span class="italic">Ophthalmology.</span> 2006;113(12):2276–2280.</p>
			<p class="h3">Treatment</p>
			<p class="body-text--no-indent-">The management of retinoblastoma has changed dramatically over the past de&#173;cade and continues to evolve. Many specialists may be involved, including ocular oncologists, pediatric ophthalmologists, ge&#173;ne&#173;ticists, ge&#173;ne&#173;tic counselors, pediatric oncologists, and radiation oncologists. External-&#173;beam radiation is seldom used to treat intraocular retinoblastoma &#173;because of its high association with development of craniofacial deformity and secondary tumors in the field of radiation. When the likelihood of salvaging vision is low, primary enucleation of eyes with advanced unilateral retinoblastoma is often performed to avoid the adverse effects of systemic chemotherapy. To prevent extraocular spread of the tumor, the surgeon should minimize manipulation of the globe and obtain a long segment of optic nerve. Small retinoblastoma tumors can often be treated with &#173;either &#173;laser photocoagulation or cryotherapy.</p>
			<p class="body-text">Primary systemic chemotherapy (chemoreduction) followed by local therapy (consolidation) has been used to spare vision for larger tumors (<span class="xref-figure">Fig 25-28</span>) and is often used in cases of bilateral retinoblastoma. Most studies of chemoreduction for retinoblastoma have used vincristine, carboplatin, and an epipodophyllotoxin. &#173;Others have added cyclospor&#173;ine. Chemotherapy is rarely successful when used alone and often requires local therapy (cryotherapy, &#173;laser photocoagulation, thermotherapy, or plaque radiotherapy) as well. Adverse effects of chemoreduction treatment include low blood count, hair loss, hearing loss, renal toxicity, neurologic and cardiac disturbances, and pos&#173;si&#173;ble increased risk for acute myelogenous leukemia.</p>
			<p class="body-text">Intra-&#173;arterial chemotherapy has recently been reported as an alternative to systemic chemoreduction for unilateral retinoblastoma in group B, C, D, or E eyes. Chemotherapy is delivered via cannulation of the ophthalmic artery in single or multiple sessions. Many chemotherapy agents have been used; melphalan is the most common. Overall, the results show higher rates of globe salvage in eyes treated initially and in &#173;those that did not respond to prior treatments. Systemic complications include neutropenia and metastasis. Ocular complications include vascular occlusion, blepharoptosis, cilia loss, temporary dysmotility, and periocular edema in the distribution of the supratrochlear artery. &#173;There is concern about the radiation that is delivered during the procedure, especially for patients with germline <span class="italic">RB1</span> gene mutations, who are at higher risk for malignant tumors.</p>
			<p class="body-text">Intravitreal chemotherapy has been used for refractory and recurrent vitreous seeding from retinoblastoma. Periocular injections have been used for adjuvant chemotherapy.</p>
			<p class="body-text">Treated retinoblastoma sometimes dis&#173;appears altogether, but more often it persists as a calcified mass (type 1, or “cottage cheese,” pattern) or a noncalcified, translucent grayish lesion (type 2, or “fish flesh,” pattern), which may be difficult to distinguish from untreated tumor. Type 3 regression has ele&#173;ments of both types 1 and 2, and type 4 regression is a flat, atrophic scar. A child with treated retinoblastoma must be observed closely for new or recurrent tumor formation, with frequent examinations &#173;under anesthesia if necessary.</p>
			<p class="body-text">Extraocular retinoblastoma, though uncommon in the United States, is still problematic in developing countries, primarily &#173;because of delay in diagnosis. The 4 major types are optic nerve involvement, orbital invasion, central ner&#173;vous system (CNS) involvement, and distant metastasis. Treatment of extraocular retinoblastoma includes intensive multimodality chemotherapy, autologous hematopoietic stem cell rescue, and external-&#173;beam radiotherapy. Long-&#173;term disease-&#173;free survival is pos&#173;si&#173;ble if the CNS is not involved; other&#173;wise, the prognosis is usually poor.</p>
			<p class="body-text">Patients with trilateral retinoblastoma have a primitive neuroectodermal tumor (PNET) of the pineal gland or parasellar region in addition to retinoblastoma. In patients with unilateral retinoblastoma, the risk of trilateral retinoblastoma has been less than 0.5%; in &#173;those with bilateral retinoblastoma, less than 5%–15%. However, the rate of trilateral retinoblastoma appears to be lower in patients treated with chemoreduction. Treatment usually involves a multimodal approach, and the prognosis is poor.</p>
			<p class="reference--journal--first">Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). <span class="italic">Ophthalmology.</span> 2010;117(8):1623–1629.</p>
			<p class="reference--journal--last">Shields CL, Alset AE, Say EA, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Caywood%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27486728"><span class="Hyperlink">Caywood E</span></a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Jabbour%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27486728"><span class="Hyperlink">Jabbour P</span></a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Shields%20JA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27486728"><span class="Hyperlink">Shields JA</span></a>. Retinoblastoma control with primary intra-&#173;arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era. <span class="italic">J Pediatr Ophthalmol Strabismus</span>. 2016;53(5):275–284.</p>
			<p class="h4-text ParaOverride-13"><span class="h4-head">Monitoring</span> Identification of <span class="italic">RB1</span> mutations is very useful in determining how frequently to monitor patients. Patients with unilateral tumors who have somatic mutations are not at risk for development of additional tumors (ocular or systemic). Patients who undergo globe salvage require frequent examinations to monitor for tumor recurrence. In &#173;these patients, examinations &#173;under anesthesia are typically performed &#173;every 4–8 weeks &#173;until age 3&#160;years. Recurrence of retinoblastoma is common and can occur years &#173;after treatment.</p>
			<p class="body-text">In patients with germline mutations, periodic MRI of the brain is performed to screen for CNS metastases and PNET, which have poor prognoses. Results of ge&#173;ne&#173;tic testing can also help determine &#173;whether siblings need to be monitored. If ge&#173;ne&#173;tic testing is not available, siblings should be monitored routinely during the first 2&#160;years of life.</p>
			<p class="body-text">&#173;Because of their risk of developing secondary malignancies, patients with germline mutations require long-&#173;term follow-up by oncologists and ophthalmologists. Nonocular tumors are common in &#173;these patients; the estimated incidence rate is 1% per year of life (eg, 10% prevalence by age 10&#160;years, 30% by age 30&#160;years). The incidence is higher among patients treated with external-&#173;beam radiation before 1 year of age. The most common secondary tumors (and the mean age at diagnosis) are PNET (2.7&#160;years), sarcoma (13&#160;years), melanoma (27&#160;years), and carcinomas (29&#160;years). For patients with second nonocular &#173;tumors, the risk of additional malignant tumors is even greater.</p>
			<p class="reference--journal--single">Correa ZM, Berry JL. Review of retinoblastoma. Pediatric Ophthalmology Education Center. April&#160;28, 2016. Available at <a href="https://www.aao.org/disease-review/review-of-retinoblastoma">https://&#173;www.&#173;aao.&#173;org/&#173;disease-&#173;review/&#173;review-&#173;of-&#173;retinoblastoma</a>.</p>
			<p class="reference--journal--mid">Woo KI, Harbour JW. Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. <span class="italic">Arch Ophthalmol.</span> 2010;128(7):865–870.</p>
			</div>
			<p class="h1 ParaOverride-14">Acquired Disorders</p>
			<div id="Chapt25_Top4">
			<p class="h2-h1">Coats Disease</p>
			<p class="body-text--no-indent-">The classic findings in Coats disease are yellow subret&#173;i&#173;nal and intraret&#173;i&#173;nal lipid exudates associated with ret&#173;i&#173;nal vascular abnormalities—&#173;most often telangiectasia, tortuosity, aneurysmal dilatations, and ret&#173;i&#173;nal capillary nonperfusion. The clinical pre&#173;sen&#173;ta&#173;tion varies, ranging from mild changes to total ret&#173;i&#173;nal detachment (<span class="xref-figure">Fig 25-29</span>).</p>
			<p class="body-text">Males are affected more frequently than females, and the condition is usually, but not always, unilateral. The average age at diagnosis is 6–8&#160;years, but the disease has also been observed in infants. The etiology of Coats disease is unknown. Associations with vari&#173;ous gene deletions have been reported, but the disease is isolated in most cases.</p>
			<p class="h3">Diagnosis</p>
			<p class="body-text--no-indent-">The diagnosis of Coats disease requires the presence of abnormal ret&#173;i&#173;nal vessels, which occasionally are small and difficult to find. The subret&#173;i&#173;nal exudate is thought to come from the leaking anomalous vessels. Fluorescein angiography may be helpful in identifying leakage from the telangiectatic vessels and in assessing the effectiveness of therapy (<span class="xref-figure">Fig </span><span class="xref-figure">25-30</span>). Oral fluorescein can be used in place of intravenous fluorescein in the ambulatory setting to monitor disease and avoid examination &#173;under anesthesia.</p>
			<p class="body-text">The differential diagnosis includes per&#173;sis&#173;tent fetal vasculature, ROP, toxocariasis, FEVR, Norrie disease, ret&#173;i&#173;nal dysplasia, endophthalmitis, leukemia, and retinoblastoma. Calcium is frequently detected by ultrasonography in retinoblastoma but is distinctly rare in Coats disease. Coats disease often pres&#173;ents with xanthocoria (yellow pupillary reflex), whereas retinoblastoma pres&#173;ents with leukocoria.</p>
			<p class="h3">Treatment</p>
			<p class="body-text--no-indent-">Treatment is directed at obliterating the abnormal leaking vessels and includes cryotherapy, &#173;laser photocoagulation, vitrectomy, and silicone oil. Exudative ret&#173;i&#173;nal detachments and subret&#173;i&#173;nal fibrosis develop in eyes with progressive disease. Once the fovea is detached and the subret&#173;i&#173;nal exudate becomes or&#173;ga&#173;nized, the prognosis for restoration of central vision is poor. Use of intravitreal bevacizumab in addition to &#173;laser treatment has been reported, but one study found that this approach was associated with a higher incidence of vitreoret&#173;i&#173;nal fibrosis and tractional ret&#173;i&#173;nal detachment.</p>
			<p class="reference--journal--first">Mulvihill A, Morris&#160;B. A population-&#173;based study of Coats disease in the United Kingdom II: investigation, treatment, and outcomes. <span class="italic">Eye (Lond).</span> 2010;24(12):1802–1807.</p>
			<p class="reference--journal--last">Ramasubramanian A, Shields CL. Bevacizumab for Coats disease with exudative ret&#173;i&#173;nal detachment and risk of vitreoret&#173;i&#173;nal traction. <span class="italic">Br J Ophthalmol.</span> 2012;96(3):356–359.</p>
		</div>
		</div>
		<div id="_idContainer010" class="Basic-Text-Frame">
			<table id="table001" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="table-title"><span class="table-number">Table 25-1</span> Interaction Between VEGF and IGF-I in Development of ROP</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-2">
							<p class="table-head">Phase I</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-3">
							<p class="table-indent-1">Occurs at 22–30 weeks’ gestational age</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Retina is hyperoxic (relative to intrauterine oxygen levels)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">VEGF levels are low</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Retinal blood vessels stop growing; this arrested growth is</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-bullet-list ParaOverride-15">• worsened by high oxygen levels</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-bullet-list ParaOverride-15">• worsened by low levels of IGF-I</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-bullet-list ParaOverride-15">• correlated with poor weight gain</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-5">
							<p class="table-head">Phase II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Occurs at 31–44 weeks’ gestational age</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Avascular retina is hypoxic</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">VEGF levels rise (due to the hypoxic avascular retina)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Neovascularization occurs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-5">
							<p class="table-head">Treatment of ROP</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Laser therapy destroys hypoxic avascular retina, so VEGF levels fall</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6">
							<p class="table-indent-1">Bevacizumab inhibits VEGF</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-7">
							<p class="table-footnote ParaOverride-16">IGF-I = insulin-like growth factor I; ROP = retinopathy of prematurity; VEGF = vascular endothelial growth factor.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer011" class="Basic-Text-Frame">
			<table id="table002" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="table-title"><span class="table-number">Table 25-2</span> International Classification of Retinopathy of Prematurity</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-2">
							<p class="table-body"><span class="CharOverride-4">Location:</span> zones II and III based on convention rather than strict anatomy (see Fig 25-1)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-3">
							<p class="table-indent-1"><span class="CharOverride-1">Zone I</span> (posterior pole): a circle centered on the optic disc with a radius equal to twice the distance from the center of the disc to the macula. Clinically, the temporal edge of zone I is visible with a 25 or 28 D lens, with the other edge of the field of view centered on the nasal disc margin </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Zone II:</span> a circle centered on the optic disc with a radius equal to the distance from the center of the optic disc to the nasal ora serrata </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Zone III:</span> residual crescent anterior to zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="CharOverride-4">Extent</span><span class="CharOverride-4">:</span> specified as hours of the clock as observer looks at each eye</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="CharOverride-4">Stages</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Stage 0:</span> immature vascularization, no ROP</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Stage 1:</span> presence of a demarcation line between vascularized retina posteriorly and avascular retina anteriorly (see Fig 25-2)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Stage 2:</span> presence of a ridge with height and width, with or without small tufts of fibrovascular proliferation (“popcorn”) (see Fig 25-3)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Stage 3:</span> ridge with extraretinal fibrovascular proliferation (see Fig 25-4) </p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-2">• mild fibrovascular proliferation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-2">• moderate fibrovascular proliferation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-2">• severe fibrovascular proliferation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Stage 4:</span> subtotal retinal detachment (see Fig 25-5)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-2">A. extrafoveal retinal detachment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-2">B. retinal detachment including fovea</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1"><span class="CharOverride-1">Stage 5:</span> total retinal detachment; open or closed funnel</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-4"><span class="CharOverride-4">Plus disease</span><span class="CharOverride-4">:</span> venous dilatation and arteriolar tortuosity present in posterior pole retinal vessels in at least 2 quadrants of the retina; standard photograph used to define the minimum amount of vascular abnormalities necessary to make the diagnosis; plus symbol (+) added to ROP stage denotes presence of plus disease (eg, stage 3 + ROP)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-4"><span class="CharOverride-4">Pre–plus disease</span><span class="CharOverride-4">:</span> venous dilatation and arteriolar tortuosity in the posterior pole but not as severe as the vascular abnormalities seen in plus disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-4"><span class="CharOverride-4">Aggressive posterior ROP:</span> zone I or posterior zone II ROP associated with plus disease involving all 4 quadrants of the posterior pole retinal vessels, shunt vessels, and flat neovascularization at the junction between vascularized and avascular retina. Without treatment, typically progresses quickly to stage 4 or 5 ROP. Was formerly known as <span class="CharOverride-1">Rush disease</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-7">
							<p class="table-source-note">D = diopter.</p>
							<p class="table-source-note">Information from International Committee for the Classification of Retinopathy of Prematurity. The Inter&#173;national Classification of Retinopathy of Prematurity revisited. <span class="CharOverride-1">Arch Ophthalmol.</span> 2005;123(7):991–999.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer014">
				<div id="_idContainer012" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-8020.png" alt="" />
				</div>
				<div id="_idContainer013" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-1</span> Schematic of the retina of the right and left eyes, showing the area of zones I <span class="figure-caption-italic">(red),</span> II <span class="figure-caption-italic">(yellow),</span> and III <span class="figure-caption-italic">(green),</span> which are used to describe the location of retinopathy of prematurity (ROP). The extent of ROP is specified as hours of the clock.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer017">
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-2</span> Stage 1 ROP. The demarcation line has no height. <span class="figure-source-note">(Courtesy of Daniel Weaver, MD.)</span></p>
				</div>
				<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-8021.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer020">
				<div id="_idContainer018" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-3</span> Stage 2 ROP. The demarcation line has height and width, creating a ridge. <span class="figure-source-note">(Courtesy of Andrea Molinari, MD.)</span></p>
				</div>
				<div id="_idContainer019" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-8022.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer023">
				<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-8023.jpg" alt="" />
				</div>
				<div id="_idContainer022" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-4</span> Stage 3 ROP. Ridge with extraretinal fibrovascular proliferation. <span class="figure-source-note">(Reproduced with permission from Lueder GT. </span><span class="figure-source-emphasis">Pediatric Practice Ophthalmology.</span><span class="figure-source-note"> New York: McGraw-Hill; 2011:232.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer026">
				<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10163.png" alt="" />
				</div>
				<div id="_idContainer025" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-5</span> Subtotal extrafoveal retinal detachment in the right eye of a patient with stage 4A ROP treated with laser. <span class="figure-source-note">(Courtesy of Robert W. Hered, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer029">
				<div id="_idContainer027" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-6</span> Plus disease. <span class="figure-source-note">(Reproduced with pe</span><span class="figure-source-note">r</span><span class="figure-source-note">&#173;mission from Lueder GT. </span><span class="figure-source-emphasis">Pediatric Practice Ophthalmology.</span><span class="figure-source-note"> New York: McGraw-Hill; 2011:231.)</span></p>
				</div>
				<div id="_idContainer028" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-8025.jpg" alt="" />
				</div>
			</div>
		</div>
		<div id="_idContainer030" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 25-7</span> Pre–plus disease. <span class="figure-source-note">(Courtesy of Dan</span><span class="figure-source-note">iel Weaver, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer033">
				<div id="_idContainer031" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10164.png" alt="" />
				</div>
				<div id="_idContainer032" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-8</span> Aggressive posterior ROP, left eye, prior to treatment <span class="figure-caption-bold">(A)</span> and shortly after laser treatment <span class="figure-caption-bold">(B).</span> <span class="figure-source-note">(Courtesy of Robert W. Hered, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer034" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-8026.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer035" class="Basic-Text-Frame">
			<table id="table003" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-14" />
					<col class="_idGenTableRowColumn-13" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 25-3</span> ETROP Classification of ROP</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-head">Type 1</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-indent-1">Zone I, any stage ROP with plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Zone I, stage 3 ROP without plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Zone II, stage 2 or 3 ROP with plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-head">Type 2</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-indent-1">Zone I, stage 1 or 2 ROP without plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-indent-1">Zone II, stage 3 ROP without plus disease</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-7" colspan="3">
							<p class="table-footnote">ETROP = Early Treatment for Retinopathy of Prematurity.</p>
							<p class="table-source-note">Modified from Wallace DK. Retinopathy of prematurity. <span class="CharOverride-1">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Academy of Ophthalmology; 2008, module 12:p 4.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer036" class="Basic-Text-Frame">
			<table id="table004" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-1">
							<p class="table-title"><span class="table-number">Table 25-4</span> Recommended Intervals of Follow-up Eye Examinations for ROP Without Plus Disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-9">
							<p class="table-head">1 Week or Less</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-10">
							<p class="table-indent-1">Immature vascularization: zone I or posterior zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Stage 1 or 2 ROP: zone I</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Stage 3 ROP: zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Presence or suspected presence of aggressive posterior ROP</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-12">
							<p class="table-head">1 to 2 Weeks</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Immature vascularization: posterior zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Stage 2 ROP: zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Unequivocally regressing ROP: zone I</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-12">
							<p class="table-head">2 Weeks</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Stage 1 ROP: zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Immature vascularization: zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Unequivocally regressing ROP: zone II</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-12">
							<p class="table-head">2 to 3 Weeks</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table CellOverride-11">
							<p class="table-indent-1">Stage 1 or 2 ROP: zone III</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-13">
							<p class="table-indent-1">Regressing ROP: zone III</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-7">
							<p class="table-source-note">Information from Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. <span class="CharOverride-1">Pediatrics.</span> 2013;131(1):189–195.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer037" class="Basic-Text-Frame">
			<table id="table005" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-18" />
					<col class="_idGenTableRowColumn-19" />
					<col class="_idGenTableRowColumn-20" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-2">
						<td class="No-Table-Style CellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 25-5</span> Criteria for Discontinuation of ROP Screening Examinations<span class="CharOverride-5">a</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style CellOverride-14" />
						<td class="No-Table-Style CellOverride-15">
							<p class="table-body">Fully vascularized retina</p>
						</td>
						<td class="No-Table-Style CellOverride-16" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-17" />
						<td class="No-Table-Style CellOverride-18">
							<p class="table-body">Zone III vascularization without previous zone I or II ROP</p>
						</td>
						<td class="No-Table-Style CellOverride-18" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-19" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Lack of development of prethreshold or worse ROP by 50 weeks’ postmenstrual age</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-21" />
						<td class="No-Table-Style CellOverride-21">
							<p class="table-title ParaOverride-17"><span class="CharOverride-6">Regression of ROP in zone III without abnormal vascular tissue capable of reactivation in zone II or III</span></p>
						</td>
						<td class="No-Table-Style CellOverride-21" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-21">
						<td class="No-Table-Style CellOverride-7" colspan="3">
							<p class="table-footnote"><span class="CharOverride-7">a </span>May consider discontinuation if any of the criteria are met. Applies to infants who did not require treatment.</p>
							<p class="table-source-note">Adapted from Shulman JP, Hobbs R, Hartnett ME. Retinopathy of prematurity: evolving concepts in diagnosis and management. <span class="CharOverride-1">Focal Points: Clinical Modules for Ophthalmologists</span>. San Francisco: American Academy of Ophthalmology; 2015, module 1.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer040">
				<div id="_idContainer038" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-0625.jpg" alt="" />
				</div>
				<div id="_idContainer039" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-9</span> Laser photocoagulation applied anterior to avascular retina. Laser treatment should not be applied directly to the ridge. Note the thick band of neovascularization and plus disease. <span class="figure-source-note">(Courtesy of Philip J. Ferrone, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer043">
				<div id="_idContainer041" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10167.png" alt="" />
				</div>
				<div id="_idContainer042" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-10</span> Posterior pole traction and dragging of the macula (right eye), a sequela of ROP. <span class="figure-source-note">(Courtesy of Robert W. Hered, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer046">
				<div id="_idContainer044" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2333.jpg" alt="" />
				</div>
				<div id="_idContainer045" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-11</span> Pseudoexotropia in a fixating left eye in ROP. The patient has a positive angle kappa as a result of macular dragging.</p>
				</div>
			</div>
		</div>
		<div id="_idContainer047" class="Basic-Text-Frame">
			<table id="table006" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-22" />
					<col class="_idGenTableRowColumn-23" />
					<col class="_idGenTableRowColumn-22" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-2">
						<td class="No-Table-Style CellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 25-6</span> Differential Diagnosis of Paradoxical Pupils</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style CellOverride-22" />
						<td class="No-Table-Style CellOverride-22">
							<p class="table-body">Achromatopsia (complete, incomplete, or blue-cone monochromatism)</p>
						</td>
						<td class="No-Table-Style CellOverride-22" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-18" />
						<td class="No-Table-Style CellOverride-18">
							<p class="table-body">Albinism</p>
						</td>
						<td class="No-Table-Style CellOverride-18" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Best disease</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Congenital stationary night blindness</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Leber congenital amaurosis</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Optic nerve hypoplasia</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-21" />
						<td class="No-Table-Style CellOverride-21">
							<p class="table-body">Retinitis pigmentosa</p>
						</td>
						<td class="No-Table-Style CellOverride-21" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer050">
				<div id="_idContainer048" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2335.jpg" alt="" />
				</div>
				<div id="_idContainer049" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-12</span> Leber congenital amaurosis with marbleized fundus.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer053">
				<div id="_idContainer051" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2336-A.jpg" alt="" />
				</div>
				<div id="_idContainer052" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-13</span> Aicardi syndrome. Fundus photograph showing optic disc coloboma and chorioretinal lacunae.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer056">
				<div id="_idContainer054" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10168.png" alt="" />
				</div>
				<div id="_idContainer055" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-14</span> Stargardt disease. Macular atrophy, pisciform yellow-white flecks, and a beaten-bronze appearance. Note the peripapillary sparing of retina. <span class="figure-source-note">(Courtesy of Marc T. Mathias, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer059">
				<div id="_idContainer057" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10169.png" alt="" />
				</div>
				<div id="_idContainer058" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-15</span> Fundus photographs from a patient with Stargardt disease. The right eye <span class="figure-caption-bold">(A)</span> and left eye <span class="figure-caption-bold">(B)</span> demonstrate classic pisciform yellow-white flecks throughout the macula, with mottling of the central retinal pigment epithelium (RPE). Corresponding right <span class="figure-caption-bold">(C)</span> and left <span class="figure-caption-bold">(D)</span> fundus autofluorescence (FAF) images reveal mottled hypo- and hyperautofluorescence with hyperautofluorescent flecks (corresponding to the pisciform flecks) and a bull’s-eye maculopathy, greater in the left eye than in the right eye. <span class="figure-source-note">(Courtesy of Marc T. Mathias, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer062">
				<div id="_idContainer060" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-16</span> Best disease, “egg yolk” stage. <span class="figure-source-note">(Courtesy of Joseph Morales, CRA, COA. Cover image for </span><span class="figure-source-emphasis">Ophthalmology Retina</span><span class="figure-source-note"> [Sept/Oct 2017 issue].)</span></p>
				</div>
				<div id="_idContainer061" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10174.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer063" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10175.png" alt="" />
			</div>
		</div>
		<div id="_idContainer064" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 25-17</span> Best disease. <span class="figure-caption-bold">A,</span> Left eye with vitelliform lesion and central dome-shaped choroidal neovascular membrane (CNVM). <span class="figure-caption-bold">B,</span> Right eye with central macular hyperautofluorescence due to vitelliform material, as seen on FAF imaging. <span class="figure-caption-bold">C,</span> Fluorescein angiography image (right eye) reveals central macular hyperfluorescence due to staining of vitelliform material. <span class="figure-caption-bold">D,</span> Fluorescein angiography image (left eye) shows late central hyperfluorescence from leakage of CNVM. <span class="figure-caption-bold">E,</span> Spectral-domain OCT (SD-OCT) image (right eye) reveals subretinal hyperreflective material with a hyporeflective cleft corresponding to the vitelliform lesion. <span class="figure-caption-bold">F</span><span class="figure-caption-bold">,</span> SD-OCT image (left eye) reveals a large subfoveal pigment epithelial detachment with subretinal hyperreflective material and subretinal fluid. <span class="figure-source-note">(Courtesy of Marc T. Mathias, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer065" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10182.png" alt="" />
			</div>
		</div>
		<div id="_idContainer066" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 25-18</span> Juvenile retinoschisis. <span class="figure-caption-bold">A,</span> SD-OCT image shows schisis of retina. <span class="figure-caption-bold">B,</span> Combined tractional and rhegmatogenous retinal detachment. <span class="figure-source-note">(Courtesy of Scott C. Oliver, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer069">
				<div id="_idContainer067" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10185.png" alt="" />
				</div>
				<div id="_idContainer068" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-19</span> Three-year-old with juvenile retinoschisis. <span class="figure-caption-bold">A,</span> Central and extensive peripheral retinoschisis with mild vitreous and preretinal hemorrhage. There is a large circumferential tractional retinal detachment around the arcades, encroaching on the central macula. A retinal hole is also present. <span class="figure-caption-bold">B,</span> Fluorescein angiography reveals an extensive tractional detachment. <span class="figure-caption-bold">C,</span> Macular OCT image demonstrates retinoschisis with a tractional detachment and subretinal fluid encroaching on the fovea. <span class="figure-source-note">(Courtesy of Marc T. Mathias, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer072">
				<div id="_idContainer070" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10189.png" alt="" />
				</div>
				<div id="_idContainer071" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-20</span> Knobloch syndrome. <span class="figure-caption-bold">A,</span> With severe chorioretinal atrophy. <span class="figure-caption-bold">B,</span> With cryptless iris. <span class="figure-caption-bold">C,</span> With scalp abnormality. <span class="figure-source-note">(Courtesy of Arif O. Khan, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer075">
				<div id="_idContainer073" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10193.png" alt="" />
				</div>
				<div id="_idContainer074" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-21</span> Familial exudative vitreoretinopathy. <span class="figure-caption-bold">A,</span> Tractional retinal detachment with a knot of anterior fibrotic tissue. <span class="figure-caption-bold">B,</span> Tractional detachment treated with a radially oriented sponge. Note the subretinal exudates. <span class="figure-caption-bold">C,</span> Fluorescein angiography image shows peripheral avascular retina and hyperfluorescence from leakage of peripheral vessels. <span class="figure-source-note">(Courtesy of Scott C. Oliver, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer078">
				<div id="_idContainer076" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2207.png" alt="" />
				</div>
				<div id="_idContainer077" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-22</span> Congenital hypertrophy of the RPE (CHRPE). Examples of varying clinical appearances. <span class="figure-caption-bold">A,</span> Small lesion. <span class="figure-caption-bold">B,</span> Medium-sized lesion; note the homogeneous black color and well-defined margins of this nummular lesion. <span class="figure-caption-bold">C,</span> Color fundus photograph of a large lesion. <span class="figure-caption-bold">D,</span>&#160;Corresponding fluorescein angiogram of the large lesion. Note the loss of RPE architecture and highlighted choroidal vasculature. <span class="figure-source-note">(Parts A, C, and D courtesy of Timothy G. Murray, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer081">
				<div id="_idContainer079" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10197.png" alt="" />
				</div>
				<div id="_idContainer080" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-23</span> Gardner Syndrome. <span class="figure-caption-bold">A,</span> Ultra-wide-angle fundus photograph shows multiple pigmented retinal lesions with areas of depigmentation oriented radially to the optic nerve. <span class="figure-caption-bold">B, </span>FAF reveals areas of hypo- and hyperautofluorescence within pigmented lesions. <span class="figure-caption-bold">C,</span> Retinal lesion with a “fish-tail” configuration. <span class="figure-source-note">(Parts A and B courtesy of Cara E. Capitena, MD; part C courtesy of Robert W. Hered, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer084">
				<div id="_idContainer082" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2367-A.jpg" alt="" />
				</div>
				<div id="_idContainer083" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-24</span> Leukocoria of the right eye, which is visible in this family photograph of a 1-year-old girl with retinoblastoma. <span class="figure-source-note">(Courtesy of A. Linn Murphree, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer085" class="Basic-Text-Frame">
			<table id="table007" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-22" />
					<col class="_idGenTableRowColumn-23" />
					<col class="_idGenTableRowColumn-22" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-2">
						<td class="No-Table-Style CellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 25-7</span> Differential Diagnosis of Leukocoria</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style CellOverride-22" />
						<td class="No-Table-Style CellOverride-22">
							<p class="table-body">Cataract</p>
						</td>
						<td class="No-Table-Style CellOverride-22" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-18" />
						<td class="No-Table-Style CellOverride-18">
							<p class="table-body">Coats disease</p>
						</td>
						<td class="No-Table-Style CellOverride-18" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Coloboma of choroid or optic disc</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Congenital retinal fold</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Corneal opacity</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Familial exudative vitreoretinopathy</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">High myopia or anisometropia </p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Myelinated nerve fibers</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Norrie disease</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Organizing vitreous hemorrhage</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Persistent fetal vasculature</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Photographic artifact</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Retinal detachment</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Retinal dysplasia</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Retinoblastoma</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-body">Retinopathy of prematurity</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style CellOverride-20" />
						<td class="No-Table-Style CellOverride-20">
							<p class="table-title"><span class="CharOverride-6">Toxocariasis</span></p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style CellOverride-21" />
						<td class="No-Table-Style CellOverride-21">
							<p class="table-body">Uveitis</p>
						</td>
						<td class="No-Table-Style CellOverride-21" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer088">
				<div id="_idContainer086" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-25</span> Fundus photograph showing multiple endophytic retinoblastoma lesions, left eye. <span class="figure-source-note">(Courtesy of A. Linn Murphree, MD.)</span></p>
				</div>
				<div id="_idContainer087" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2367-B.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer091">
				<div id="_idContainer089" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-26</span> Endophytic retinoblastoma with vitreous seeding.</p>
				</div>
				<div id="_idContainer090" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2368-A.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer094">
				<div id="_idContainer092" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-2368-B.jpg" alt="" />
				</div>
				<div id="_idContainer093" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-27</span> Exophytic retinoblastoma with overlying detached retina.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer201" class=" _idGenObjectLayout-2">
				<div id="_idContainer095" class="Basic-Text-Frame">
					<table id="table008" class="No-Table-Style TableOverride-1">
						<colgroup>
							<col class="_idGenTableRowColumn-24" />
							<col class="_idGenTableRowColumn-25" />
							<col class="_idGenTableRowColumn-26" />
							<col class="_idGenTableRowColumn-25" />
							<col class="_idGenTableRowColumn-27" />
							<col class="_idGenTableRowColumn-28" />
							<col class="_idGenTableRowColumn-29" />
							<col class="_idGenTableRowColumn-28" />
							<col class="_idGenTableRowColumn-30" />
							<col class="_idGenTableRowColumn-28" />
							<col class="_idGenTableRowColumn-29" />
							<col class="_idGenTableRowColumn-28" />
							<col class="_idGenTableRowColumn-31" />
						</colgroup>
						<tbody>
							<tr class="No-Table-Style _idGenTableRowColumn-5">
								<td class="No-Table-Style CellOverride-23 _idGenCellOverride-1" colspan="13">
									<p class="table-title"><span class="table-number">Table 25-8</span> Genetic Counseling for Retinoblastoma</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-2">
								<td class="No-Table-Style CellOverride-24">
									<p class="table-subhead ParaOverride-6">If Parent:   </p>
								</td>
								<td class="No-Table-Style CellOverride-25 _idGenCellOverride-2" colspan="4">
									<p class="table-subhead">Has Bilateral Retinoblastoma</p>
								</td>
								<td class="No-Table-Style CellOverride-26 _idGenCellOverride-2" colspan="4">
									<p class="table-subhead">Has Unilateral Retinoblastoma</p>
								</td>
								<td class="No-Table-Style CellOverride-27" colspan="4">
									<p class="table-subhead">Is Unaffected</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-32">
								<td class="No-Table-Style CellOverride-28">
									<p class="table-body">Chance of</p>
									<p class="table-body">offspring having</p>
									<p class="table-body">retinoblastoma</p>
								</td>
								<td class="No-Table-Style CellOverride-29" colspan="3">
									<p class="table-body ParaOverride-18">45%</p>
									<p class="table-body ParaOverride-18">affected</p>
								</td>
								<td class="No-Table-Style CellOverride-30">
									<p class="table-body ParaOverride-18">55%</p>
									<p class="table-body ParaOverride-19">unaffected</p>
								</td>
								<td class="No-Table-Style CellOverride-31" colspan="3">
									<p class="table-body ParaOverride-18">7%–15%</p>
									<p class="table-body ParaOverride-18">affected</p>
								</td>
								<td class="No-Table-Style CellOverride-32">
									<p class="table-body ParaOverride-18">85%–93%</p>
									<p class="table-body ParaOverride-20">unaffected</p>
								</td>
								<td class="No-Table-Style CellOverride-33" colspan="3">
									<p class="table-body ParaOverride-18">&lt;1%</p>
									<p class="table-body ParaOverride-18">affected</p>
								</td>
								<td class="No-Table-Style CellOverride-28">
									<p class="table-body ParaOverride-18">99%</p>
									<p class="table-body ParaOverride-18">unaffected</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-33">
								<td class="No-Table-Style CellOverride-4">
									<p class="table-body">Laterality</p>
								</td>
								<td class="No-Table-Style CellOverride-4">
									<p class="table-body ParaOverride-18">85%</p>
									<p class="table-body ParaOverride-18">bilateral</p>
								</td>
								<td class="No-Table-Style CellOverride-34" colspan="2">
									<p class="table-body ParaOverride-18">15%</p>
									<p class="table-body ParaOverride-18">unilateral</p>
								</td>
								<td class="No-Table-Style CellOverride-35">
									<p class="table-body ParaOverride-18">0%</p>
								</td>
								<td class="No-Table-Style CellOverride-36">
									<p class="table-body ParaOverride-18">85%</p>
									<p class="table-body ParaOverride-18">bilateral</p>
								</td>
								<td class="No-Table-Style CellOverride-4" colspan="2">
									<p class="table-body ParaOverride-18">15%</p>
									<p class="table-body ParaOverride-18">unilateral</p>
								</td>
								<td class="No-Table-Style CellOverride-37">
									<p class="table-body ParaOverride-18">0%</p>
								</td>
								<td class="No-Table-Style CellOverride-36">
									<p class="table-body ParaOverride-18">33%</p>
									<p class="table-body ParaOverride-18">bilateral</p>
								</td>
								<td class="No-Table-Style CellOverride-38" colspan="2">
									<p class="table-body ParaOverride-18">67%</p>
									<p class="table-body ParaOverride-18">unilateral</p>
								</td>
								<td class="No-Table-Style CellOverride-4">
									<p class="table-body ParaOverride-18">0%</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-34">
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body">Focality</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">100%</p>
									<p class="table-body ParaOverride-18">multi-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">96%</p>
									<p class="table-body ParaOverride-18">multi-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">4%</p>
									<p class="table-body ParaOverride-18">uni-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-40">
									<p class="table-body ParaOverride-18">0%</p>
								</td>
								<td class="No-Table-Style CellOverride-41">
									<p class="table-body ParaOverride-18">100%</p>
									<p class="table-body ParaOverride-18">multi-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">96%</p>
									<p class="table-body ParaOverride-18">multi-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">4%</p>
									<p class="table-body ParaOverride-18">uni-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-42">
									<p class="table-body ParaOverride-18">0%</p>
								</td>
								<td class="No-Table-Style CellOverride-41">
									<p class="table-body ParaOverride-18">100%</p>
									<p class="table-body ParaOverride-18">multi-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">15%</p>
									<p class="table-body ParaOverride-18">multi-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">85%</p>
									<p class="table-body ParaOverride-18">uni-</p>
									<p class="table-body ParaOverride-18">focal</p>
								</td>
								<td class="No-Table-Style CellOverride-39">
									<p class="table-body ParaOverride-18">0%</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-35">
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body">Chance of next</p>
									<p class="table-body">sibling having</p>
									<p class="table-body">retinoblastoma</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-44">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-45">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">45%</p>
								</td>
								<td class="No-Table-Style CellOverride-46">
									<p class="table-body ParaOverride-18">7%–15%</p>
								</td>
								<td class="No-Table-Style CellOverride-45">
									<p class="table-body ParaOverride-18">5%*</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">&lt;1%*</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">&lt;1%*</p>
								</td>
								<td class="No-Table-Style CellOverride-43">
									<p class="table-body ParaOverride-18">&lt;1%</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-36">
								<td class="No-Table-Style CellOverride-47 _idGenCellOverride-2" colspan="5" />
								<td class="No-Table-Style CellOverride-48 _idGenCellOverride-2" colspan="4" />
								<td class="No-Table-Style CellOverride-48" colspan="4">
									<p class="table-body ParaOverride-18">*If parent is a carrier, then 45%</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-2">
								<td class="No-Table-Style CellOverride-49" colspan="13">
									<p class="table-source-note">Table created by David H. Abramson, MD.</p>
								</td>
							</tr>
						</tbody>
					</table>
				</div>
				<div id="_idContainer098">
					<div id="_idContainer096" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer097" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer101">
					<div id="_idContainer099" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer100" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer104">
					<div id="_idContainer102" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer103" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer111">
					<div id="_idContainer107">
						<div id="_idContainer105" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer106" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
					<div id="_idContainer110">
						<div id="_idContainer108" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer109" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
				</div>
				<div id="_idContainer118">
					<div id="_idContainer114">
						<div id="_idContainer112" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer113" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
					<div id="_idContainer117">
						<div id="_idContainer115" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer116" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
				</div>
				<div id="_idContainer125">
					<div id="_idContainer121">
						<div id="_idContainer119" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer120" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
					<div id="_idContainer124">
						<div id="_idContainer122" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer123" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
				</div>
				<div id="_idContainer128">
					<div id="_idContainer126" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer127" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer131">
					<div id="_idContainer129" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer130" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer134">
					<div id="_idContainer132" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer133" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer137">
					<div id="_idContainer135" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer136" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer140">
					<div id="_idContainer138" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer139" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer143">
					<div id="_idContainer141" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer142" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer150">
					<div id="_idContainer146">
						<div id="_idContainer144" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer145" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
					<div id="_idContainer149">
						<div id="_idContainer147" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer148" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
				</div>
				<div id="_idContainer157">
					<div id="_idContainer153">
						<div id="_idContainer151" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer152" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
					<div id="_idContainer156">
						<div id="_idContainer154" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer155" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
				</div>
				<div id="_idContainer164">
					<div id="_idContainer160">
						<div id="_idContainer158" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer159" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
					<div id="_idContainer163">
						<div id="_idContainer161" class="_idGenObjectStyleOverride-2">
						</div>
						<div id="_idContainer162" class="_idGenObjectStyleOverride-3">
						</div>
					</div>
				</div>
				<div id="_idContainer167">
					<div id="_idContainer165" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer166" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer170">
					<div id="_idContainer168" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer169" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer173">
					<div id="_idContainer171" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer172" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer176">
					<div id="_idContainer174" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer175" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer179">
					<div id="_idContainer177" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer178" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer182">
					<div id="_idContainer180" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer181" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer185">
					<div id="_idContainer183" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer184" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer188">
					<div id="_idContainer186" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer187" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer191">
					<div id="_idContainer189" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer190" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer194">
					<div id="_idContainer192" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer193" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer197">
					<div id="_idContainer195" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer196" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
				<div id="_idContainer200">
					<div id="_idContainer198" class="_idGenObjectStyleOverride-2">
					</div>
					<div id="_idContainer199" class="_idGenObjectStyleOverride-3">
					</div>
				</div>
			</div>
		</div>
		<div id="_idContainer202" class="Basic-Text-Frame">
			<table id="table009" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-37" />
					<col class="_idGenTableRowColumn-38" />
					<col class="_idGenTableRowColumn-39" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-23 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 25-9</span> International Classification of Retinoblastoma</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table CellOverride-50">
							<p class="table-subhead ParaOverride-6">Group</p>
						</td>
						<td class="Basic-Table CellOverride-50" />
						<td class="Basic-Table CellOverride-50">
							<p class="table-subhead ParaOverride-6">Features</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-2">
							<p class="table-body">A</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-body">Small tumors (≤3 mm) confined to the retina; &gt;3 mm from the fovea; &gt;1.5 mm from the optic disc</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">B</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Tumors (&gt;3 mm) confined to the retina in any location, with clear subretinal fluid ≤6&#160;mm from the tumor margin</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-40">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">C</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Localized vitreous and/or subretinal seeding (&lt;6 mm total from tumor margin)</p>
							<p class="table-body">If there is more than 1 site of subretinal or vitreous seeding, the total of these sites is <br />&lt;6 mm</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">D</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Diffuse vitreous and/or subretinal seeding (≥6 mm total from tumor margin)</p>
							<p class="table-body">If there is more than 1 site of subretinal or vitreous seeding, the total of these sites is <br />≥6 mm</p>
							<p class="table-body">Subretinal fluid &gt;6 mm from tumor margin</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-41">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">E</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">No visual potential or</p>
							<p class="table-body">Presence of any of the following:</p>
							<p class="table-bullet-list2 ParaOverride-21">• tumor in the anterior segment</p>
							<p class="table-bullet-list2 ParaOverride-21">• tumor in or on the ciliary body</p>
							<p class="table-bullet-list2 ParaOverride-21">• neovascular glaucoma</p>
							<p class="table-bullet-list2 ParaOverride-21">• vitreous hemorrhage obscuring the tumor or significant hyphema</p>
							<p class="table-bullet-list2 ParaOverride-21">• phthisical or prephthisical eye</p>
							<p class="table-bullet-list2 ParaOverride-21">• orbital cellulitis-like presentation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-7" colspan="3">
							<p class="table-source-note">Modified from Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success.<span class="CharOverride-1"> Ophthalmology.</span> 2006;113(12):2276–2280.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer205">
				<div id="_idContainer203" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-3609.png" alt="" />
				</div>
				<div id="_idContainer204" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-28</span> <span class="figure-caption-bold">A,</span> Left eye of an infant with bilateral retinoblastoma; 2 tumors straddle the optic nerve. <span class="figure-caption-bold">B,</span> After chemoreduction and laser consolidation, the tumors are nonviable. The child’s visual acuity was 20/25 at age 5 years.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer208">
				<div id="_idContainer206" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10201.png" alt="" />
				</div>
				<div id="_idContainer207" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-29</span> Advanced Coats disease with extensive subretinal exudation and total retinal detachment. Superior retinal macrocysts—associated with macroaneurysms and dilatated, tortuous vessels—are present. <span class="figure-source-note">(Courtesy of Scott C. Oliver, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer211">
				<div id="_idContainer209" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C25_p325-360-web-resources/image/AAX-10202.png" alt="" />
				</div>
				<div id="_idContainer210" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 25-30</span> Coats disease. <span class="figure-caption-bold">A,</span> Ultra-wide-angle color photograph reveals foveal exudation with temporal macroaneurysms and telangiectasias. Inset shows magnification of macroaneurysms and telangiectasias. Subtle nasal telangiectasias are also present. <span class="figure-caption-bold">B,</span> Image obtained with oral fluorescein angiography shows extensive leakage from temporal macroaneurysms, mild leakage from temporal and nasal telangiectasias, and macular leakage with some staining. <span class="figure-source-note">(Courtesy of Scott C. Oliver, MD.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
